[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 367
1. Chen CQ, Yin L, Peng CH, Ye M, Zhao R, Chen GM, Zhou HJ, Li HW, Fan YZ: [Primary diffuse large B-cell non-Hodgkin's lymphoma of the small intestine: clinicopathologic features, management, and prognosis in 24 patients]. Zhonghua Zhong Liu Za Zhi; 2007 Sep;29(9):693-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell non-Hodgkin's lymphoma of the small intestine: clinicopathologic features, management, and prognosis in 24 patients].
  • All cases were staged according to the Ann Arbor classification of lymphoma.
  • Although there was no statistically significant difference(P = 0.28) in therapy result between the CD10+ and CDO1--groups, patients with CD10+ lymphoma more frequently presented with stages I compared with those with CD10 - lymphoma (P = 0.013).
  • Five cases died of the disease.
  • The analysis of survival rate showed a longer overall survival duration in the stage I and II group compared with that of the stage III and IV group ( P = 0.0197 ) , but there was no significant difference between CD10+ and CD1- groups.
  • CONCLUSION: The primary small intestnal diffuse large B cell lymphoma patients at stage I and II respond better to therapy including surgical resection and chemotherapy than those at stage III and IV.
  • CD10+ expression is more common in stage I lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms. Intestine, Small / surgery. Lymphoma, Large B-Cell, Diffuse. Neprilysin / metabolism
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Remission Induction. Survival Rate. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246801.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


2. Wang T, Gui W, Shen Q: Primary gastrointestinal non-Hodgkin's lymphoma: clinicopathological and prognostic analysis. Med Oncol; 2010 Sep;27(3):661-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non-Hodgkin's lymphoma: clinicopathological and prognostic analysis.
  • The objective is to investigate the association between pathological type and clinical features, response to treatment and prognosis of primary gastrointestinal Non-Hodgkin's lymphoma (PGINHL).
  • In 115 (92.7%) patients of B-cell lymphoma, mucosa-associated lymphoid tissue lymphoma (MALToma) and diffuse large B-cell lymphoma (DLBCL) were 55 and 50 patients, respectively.
  • The patients of two pathological types had different clinical features including stage, B symptoms, sites of tumor, distant involvement, International Prognosis Index Score, size of tumor, and response to treatment.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Kaplan-Meier Estimate. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / mortality. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Prognosis. Proportional Hazards Models. Risk. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3874-83 [11559725.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1929-34 [10206316.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):405-7 [15101733.001]
  • [Cites] Endoscopy. 2004 Nov;36(11):1022-4 [15520925.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):339-44 [15101721.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] Am Surg. 2008 Mar;74(3):214-6 [18376684.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1093-103 [10725618.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1751-7 [14630680.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):349-52 [15958057.001]
  • [Cites] Intern Med. 2006;45(6):405-9 [16617193.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):53-8 [11249049.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):1992-9 [18647965.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1253-9 [16923554.001]
  • [Cites] Acta Oncol. 2006;45(2):202-9 [16546867.001]
  • [Cites] Nan Fang Yi Ke Da Xue Xue Bao. 2008 Feb;28(2):243-5 [18250053.001]
  • [Cites] J Pathol. 2005 Jan;205(2):255-74 [15643667.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):286-94 [10640959.001]
  • (PMID = 19565363.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM: High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol; 2005 Nov 1;23(31):7994-8002
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
  • PURPOSE: To determine the incidence of second malignancies among patients with Hodgkin's lymphoma (HL) treated with autologous hematopoietic stem cell transplantation (AHSCT) compared with patients receiving conventional therapy alone and to identify potential risk factors for their occurrence.
  • An increased risk of therapy-induced acute myeloid leukemia and therapy-induced myelodysplastic syndrome was seen for patients aged > or = 35 years (P = .03) and stage III/IV (P = .04).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hematopoietic Stem Cell Transplantation / adverse effects. Hodgkin Disease / therapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cohort Studies. Female. Humans. Incidence. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / etiology. Male. Middle Aged. Myelodysplastic Syndromes / diagnosis. Myelodysplastic Syndromes / etiology. Retrospective Studies. Risk Factors. Transplantation, Autologous


Advertisement
4. Vulto JC, Lybeert ML, Louwman MW, Poortmans PM, Coebergh JW: Population-based study of trends and variations in radiotherapy as part of primary treatment of cancer in the southern Netherlands between 1988 and 2006, with an emphasis on breast and rectal cancer. Int J Radiat Oncol Biol Phys; 2009 Jun 1;74(2):464-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Especially for breast and rectal cancer patients we studied primary RT use according to stage (breast cancer) and age and separately for the eastern and western sectors.
  • Over time, more patients with prostate and rectal cancer, fewer patients with lung and bladder cancer or Hodgkin's lymphoma, and, recently, more patients with cervical or endometrial cancer received RT.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Confidence Intervals. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasms / epidemiology. Neoplasms / radiotherapy. Netherlands / epidemiology. Odds Ratio. Radiotherapy / trends. Regression Analysis. Young Adult

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289268.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, Tarbell N, Desai S, Weitzman S, Weinstein HJ, Murphy SB: Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol; 2005 Jan 20;23(3):541-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial.
  • PURPOSE: The Pediatric Oncology Group adopted a histology-based approach to non-Hodgkin's lymphoma and treated patients with advanced large-cell lymphoma on a separate protocol (doxorubicin, vincristine, prednisone, 6-mercaptopurin, and methotrexate; APO regimen).
  • PATIENTS AND METHODS: From December 1994 to April 2000, we enrolled 180 eligible pediatric patients with stage III/IV large-cell lymphoma (LCL); 90 patients were randomly assigned to the intermediate-dose methotrexate (IDM) and high-dose cytarabine (HiDAC) arm, 85 patients to the APO arm, and five patients directly to the APO arm by study design due to CNS involvement.
  • The 4-year EFS and OS were 71.8% (SE, 6.1%) and 88.1% (SE, 4.4%), respectively, for patients with anaplastic large-cell lymphoma, and 63.8% (SE, 10.3%) and 70.3% (SE, 9.0%), respectively, for patients with diffuse large B-cell lymphoma.
  • Only 11 patients required radiation (due to unresponsive bulky disease or CNS involvement).
  • CONCLUSION: The efficacy of incorporating IDM/HiDAC in the treatment plan of pediatric and adolescent patients with advanced-stage LCL was inconclusive as to its effect on EFS, regardless of the lymphoma phenotype.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Staging
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Adult. Age Factors. Child. Child, Preschool. Cytarabine / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Humans. Infant. Infusions, Intravenous. Injections, Spinal. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15659500.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; APO combination
  •  go-up   go-down


6. Howell SJ, Searle C, Goode V, Gardener T, Linton K, Cowan RA, Harris MA, Hopwood P, Swindell R, Norman A, Kennedy J, Howell A, Wardley AM, Radford JA: The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. Br J Cancer; 2009 Aug 18;101(4):582-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage.
  • BACKGROUND: Supradiaphragmatic radiotherapy (SRT) to treat Hodgkin's lymphoma (HL) at a young age increases the risk of breast cancer (BC).
  • CONCLUSIONS: The NRASP appears to detect BC at an early stage with acceptable biopsy rates, although numbers are small.
  • [MeSH-major] Breast Neoplasms / diagnosis. Hodgkin Disease / radiotherapy. Mass Screening / methods. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adult. Female. Great Britain. Humans. Mammography. Middle Aged. Radiotherapy / adverse effects. Registries. Retrospective Studies. Risk Factors. Survivors


7. Campbell B, Wirth A, Milner A, Di Iulio J, MacManus M, Ryan G: Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure. Int J Radiat Oncol Biol Phys; 2005 Dec 1;63(5):1538-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.
  • PURPOSE: To evaluate the long-term results of salvage radiotherapy (SRT) for Hodgkin's lymphoma after chemotherapy failure.
  • METHODS AND MATERIALS: We reviewed 81 patients undergoing SRT for persistent or recurrent Hodgkin's lymphoma after chemotherapy; 19 also received conventional-dose salvage chemotherapy.
  • Of the 81 patients, 81% had Stage I-II, 25.9% had B symptoms, 14.8% had bulky disease, and 7.4% had extranodal disease.
  • The adverse prognostic factors for freedom from treatment failure were age >50 years (p < 0.001), B symptoms (p < 0.001), extranodal disease (p = 0.012), and less than a CR to the last chemotherapy regimen (p = 0.001).
  • CONCLUSIONS: Salvage radiotherapy is effective for selected patients with Hodgkin's lymphoma after chemotherapy failure and should be considered for incorporation into salvage programs.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Child, Preschool. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Recurrence. Sex Factors. Treatment Failure. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125872.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


8. Recklitis CJ, Sanchez Varela V, Ng A, Mauch P, Bober S: Sexual functioning in long-term survivors of Hodgkin's lymphoma. Psychooncology; 2010 Nov;19(11):1229-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sexual functioning in long-term survivors of Hodgkin's lymphoma.
  • OBJECTIVE: Studies of Hodgkin's lymphoma (HL) survivors have reported long-term adjustment problems including sexual dysfunction, but the prevalence and persistence of sexual problems in HL survivors have not been well characterized.
  • No associations between time since diagnosis, disease stage, and chemotherapy treatment and sexual functioning were found.
  • [MeSH-major] Hodgkin Disease / physiopathology. Sexual Behavior. Sexual Dysfunction, Physiological / physiopathology. Survivors / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Boston / epidemiology. Case-Control Studies. Cohort Studies. Data Collection. Female. Humans. Logistic Models. Male. Middle Aged. Prevalence. Sexual Dysfunctions, Psychological. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Sexual Problems in Men.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20035526.001).
  • [ISSN] 1099-1611
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS: Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant; 2007 Sep;13(9):1057-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.
  • The role of autologous stem cell transplantation (ASCT) in the treatment of follicular lymphoma is still being defined in the era of antibody therapy.
  • Here we report the long-term 12-year clinical outcomes of patients treated with autologous bone marrow transplantation (ABMT) for follicular non-Hodgkin's lymphoma (NHL) in first remission.
  • Between 1988 and 1993, advanced-stage follicular NHL patients in need of initial therapy were enrolled in 2 consecutive prospective treatment trials of either standard-dose CHOP induction (83 patients) or high-dose CHOP plus granulocyte-colony stimulating factor (G-CSF) (20 patients).
  • The only predictors of decreased progression-free survival proved to be histologic BM involvement at time of harvest (hazard ratio [HR] 2.27, 95% confidence interval [CI] 1.3-3.9, P<.004) and PCR detectable disease in the BM product after purging (HR 4.18, 95% CI 1.99-8.8, P=.0002).
  • These results at 12-year follow-up suggest that a subset of follicular lymphoma patients can experience prolonged survival with ABMT in first remission.


10. Guo HY, Zhao XM, Cao JN, Hu XC, Yin JL, Hong XN, Li J: [Prognosis of primary non-Hodgkin's lymphoma of the breast]. Zhonghua Zhong Liu Za Zhi; 2008 Mar;30(3):200-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis of primary non-Hodgkin's lymphoma of the breast].
  • OBJECTIVE: To analyze the clinical characteristics and prognosis of primary non-Hodgkin's lymphoma of the breast (PNHLB).
  • RESULTS: Of these 45 patients, 37 patients had diffuse large B cell lymphoma (DLBCL), patients with T cell or mucosa-associated lymphoid tissue (MALT) lymphoma were 4, respectively.
  • The results of Cox regression model analysis showed that international prognostic index score (IPI) (RR = 5.682, P = 0.002) and Ann Arbor stage (RR = 1.836, P = 0.040) were negative independent prognostic factors for OS.
  • IPI and Ann Arbor stage are two independent prognostic factors for survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / therapeutic use. Breast Neoplasms, Male / drug therapy. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / radiotherapy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756936.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


11. Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A, D'Alo' F, Larocca LM, Raymakers RA, Swinkels DW, Voso MT, Leone G: Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol; 2010 May 20;28(15):2538-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin.
  • PURPOSE: Cytokines play a pivotal role in Hodgkin's lymphoma (HL).
  • Higher hepcidin levels were observed in patients with more aggressive disease characteristics: stage IV disease (P = .01), presence of B symptoms (P = .03), and International Prognostic Score > 2 (P = .005).
  • [MeSH-major] Anemia / blood. Antimicrobial Cationic Peptides / blood. Hodgkin Disease / blood. Interleukin-6 / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Chemokine CCL17 / blood. Enzyme-Linked Immunosorbent Assay. Female. Ferritins / blood. Hepcidins. Humans. Inflammation Mediators / blood. Interleukin-10 / blood. Iron / blood. Male. Mass Spectrometry. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2011 Jan 10;29(2):e42; author reply e43 [21079132.001]
  • (PMID = 20406921.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / CCL17 protein, human; 0 / Chemokine CCL17; 0 / HAMP protein, human; 0 / Hepcidins; 0 / Inflammation Mediators; 0 / Interleukin-6; 130068-27-8 / Interleukin-10; 9007-73-2 / Ferritins; E1UOL152H7 / Iron
  •  go-up   go-down


12. Gujral S, Agarwal A, Gota V, Nair R, Gupta S, Pai SK, Sanger M, Shet T, Subramanian PG, Muckaden M, Laskar S: A clinicopathologic study of mantle cell lymphoma in a single center study in India. Indian J Pathol Microbiol; 2008 Jul-Sep;51(3):315-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathologic study of mantle cell lymphoma in a single center study in India.
  • We present clinical features, histopathology and results of treatment in cases of mantle cell lymphoma (MCL) at our hospital.
  • We had 93 cases (2.1%) of MCL out of total 4301 cases of non-Hodgkin's lymphoma (NHL) in a 4-year period.
  • Thirty-six (85%) patients had advanced-stage disease.
  • [MeSH-major] Lymphoma, Mantle-Cell / pathology. Lymphoma, Mantle-Cell / physiopathology
  • [MeSH-minor] Adult. Aged. Antigens, CD20 / biosynthesis. Antigens, CD43 / biosynthesis. Antigens, CD5 / biosynthesis. Antineoplastic Agents / therapeutic use. Bone Marrow / pathology. Cyclin D1 / biosynthesis. Female. Gastrointestinal Tract / pathology. Hospitals. Humans. India. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18723950.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD43; 0 / Antigens, CD5; 0 / Antineoplastic Agents; 0 / CCND1 protein, human; 0 / UN1 sialoglycoprotein, human; 136601-57-5 / Cyclin D1
  •  go-up   go-down


13. Moralidis E, Mandala E, Venizelos I, Arsos G, Zafiriadu E, Goutzioulis M, Karakatsanis C: A breast fibroadenoma mimicking an extranodal deposit of Hodgkin's lymphoma in 67Ga imaging. Br J Radiol; 2009 Mar;82(975):e58-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A breast fibroadenoma mimicking an extranodal deposit of Hodgkin's lymphoma in 67Ga imaging.
  • We present the case of a young woman with classical nodular sclerosing Hodgkin's lymphoma (clinical stage IIB).
  • A post-treatment (67)Ga scan showed complete remission of the disease with normal tracer uptake in the left breast.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Contrast Media. Fibroadenoma / radionuclide imaging. Gallium Radioisotopes. Hodgkin Disease / radionuclide imaging
  • [MeSH-minor] Diagnosis, Differential. False Positive Reactions. Female. Humans. Lymphatic Metastasis. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211906.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Gallium Radioisotopes
  •  go-up   go-down


14. Huang HQ, Lin XB, Pan ZH, Bu Q, Gao Y, Wang BF, Cai QQ, Xia ZJ, Xu RH, Jiang WQ, Guan ZZ: [CEOP regimen in the treatment for non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2007 May;29(5):391-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
  • OBJECTIVE: The aim of this study is to analyse the efficacy and toxicity of CEOP regimen in the treatment of non-Hodgkin's lymphoma (NHL).
  • 4% (67/121) had early disease (stage I or II), and 89.3% (108/121) had IPI score 0-2.
  • CONCLUSION: Our data show that CEOP regimen combined with or without radiotherapy for the involved field is effective and well tolerated by the patients with non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / chemically induced. Child. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Epirubicin / adverse effects. Epirubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Prednisone / adverse effects. Prednisone / therapeutic use. Remission Induction. Retrospective Studies. Survival Analysis. Thrombocytopenia / chemically induced. Vincristine / adverse effects. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892140.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1
  •  go-up   go-down


15. Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. Ai Zheng; 2007 Dec;26(12):1339-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is an aggressive non-Hodgkin's lymphoma (NHL) and often involves bone marrow and central nerve system.
  • The efficacy of CHOP regimen on Burkitt's lymphoma is poor.
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in children and adolescents, and observe the survival status.
  • 2006, 31 untreated Burkitt's lymphoma patients aged less than 20 were enrolled.
  • According to St Jude staging system, 1 (3.2%) was at stage I, 6 (19.4%) at stage II, 8 (25.8%) at stage III, 16 (51.6%) at stage IV; 24 (77.4%) were at stage III/IV.
  • According to clinical stage, lactate dehydrogenase (LDH) level and treatment response, these patients were divided into low, moderate and high risk groups.
  • They received modified B-NHL-BFM-90 protocol: cytotoxic drugs such as cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesin, dexamethasone, cytarabinec/HD-cytarabine and intrathecal injection.
  • Of the 30 patients, 25 (83.3%) achieved complete remission (CR), 3 (10.0%) achieved partial remission (PR), 2 (6.7%) had progressive disease (PD)û 1 had tumor relapse.
  • At a median follow-up of 33 months (range, 3-98 months), the 3-year event-free survival (EFS) rate was 86.0% for all patients, with 100% for stage I/II patients and 82.1% for stage III/IV patients, 100% for low risk group, 92.0% for moderate risk group, and 70.0% for high risk group.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol can improve the responses and survival of Burkitt's lymphoma in Chinese children and adolescents, with tolerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. L-Lactate Dehydrogenase / blood. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. Remission Induction. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076797.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


16. Stanojević GZ, Stojanović MP, Stojanović MM, Krivokapić Z, Jovanović MM, Katić VV, Jeremić MM, Branković BR: Non-Hodgkin's lymphomas of the large bowel-clinical characteristics, prognostic factors and survival. Acta Chir Iugosl; 2008;55(3):109-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas of the large bowel-clinical characteristics, prognostic factors and survival.
  • The aims of this study were to review the clinical presentation of non-Hodgkin's lymphomas of the large bowel, to analyze the prognostic factors using univariate and multivariate methods, as well as the overall survival.
  • The following clinical information such as age, gender, symptoms, tumor localization, operation performed, histology grade, stage of disease, and adjuvant chemotherapy was obtained.
  • Tumor stage and operation type were independent prognostic factors for survival, as determined by multivariate analysis.
  • Our results showed that tumor stage and operation type should be considered as the most important prognostic factors in patients with primary non-Hodgkin's lymphomas of the large bowel.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069702.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


17. Wei G, Yuping Z, Jun W, Bing Y, Qiaohua Z: CA125 expression in patients with non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Jul;47(7):1322-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CA125 expression in patients with non-Hodgkin's lymphoma.
  • The present study investigated the possible clinical significance of serum CA125 levels in patients with non-Hodgkin's lymphoma (NHL) and the mechanism of secretion.
  • Serum CA125 levels were associated with clinical stage, effusions, high serum lactate dehydrogenase and beta2-M levels, and response to therapy.
  • The immunohistochemical study suggested that CA125 appeared not to be secreted by lymphoma cells directly.
  • [MeSH-major] CA-125 Antigen / biosynthesis. CA-125 Antigen / blood. Gene Expression Regulation, Neoplastic. Lymphoma, Non-Hodgkin / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Regression Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923563.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


18. Hauenstein E, Seidl S, Schneider KT, Fischer T: Stillbirth in week 19 of pregnancy followed by maternal death as a consequence of refused chemotherapy for non-hodgkin's lymphoma--significance of adjuvant chemotherapy in women of reproductive age. Onkologie; 2010;33(12):692-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stillbirth in week 19 of pregnancy followed by maternal death as a consequence of refused chemotherapy for non-hodgkin's lymphoma--significance of adjuvant chemotherapy in women of reproductive age.
  • Hematologists and gynecologists have to treat more and more female patients who wish to become pregnant despite their disease and/or after finishing treatment.
  • CASE REPORT: We report on a 28-year-old patient with highly malignant non-Hodgkin's lymphoma (peripheral T cell lymphoma, Ann Arbor stage IV) and main manifestation at the gastric antrum, with a distinct wish for becoming pregnant.
  • After she had conceived, the disease recurred, followed by stillbirth in week 19 of gestation and death due to gastric perforation and septic shock.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / toxicity. Infertility, Female / chemically induced. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / surgery. Pregnancy Complications, Neoplastic / drug therapy. Pregnancy Complications, Neoplastic / surgery. Stillbirth. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Treatment Refusal
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Fatal Outcome. Female. Gastrectomy. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / toxicity. Pregnancy. Pregnancy Trimester, Second. Pyloric Antrum / pathology. Rupture, Spontaneous. Shock, Septic / pathology. Stomach Rupture / parasitology. Vincristine / administration & dosage. Vincristine / toxicity


19. Gao Y, Huang HQ, Lin XB, Cai QQ, Pan ZH, Wang BF, Bu Q: [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma]. Ai Zheng; 2007 Aug;26(8):909-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: The prognosis of relapsed or refractory T-cell non-Hodgkin's lymphoma (T-NHL) is poor.
  • Multivariate analysis showed that serum lactate dehydrogenase (LDH) level (P=0.010), second-line Ann Arbor stage (P=0.009), second-line IPI score (P=0.015), autologous stem cell transplantation (P=0.026), performance status (P=0.002), and IMVP-16 regimen (P=0.026) were independent prognostic factors of relapsed or refractory T-NHL.
  • The prognosis of this disease is poor and the addition of intensive treatments, such as stem cell transplantation, should be considered when alleviated after chemotherapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697558.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


20. Blayney DW, McGuire BW, Cruickshank SE, Johnson DH: Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma. Oncologist; 2005 Feb;10(2):138-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
  • We conducted two phase I studies, in non-small cell lung cancer (NSCLC) and in lymphoma, to explore the possibility of intensifying chemotherapy by compressing the delivery of and escalating the dose of standard combination chemotherapy.
  • One study used etoposide and cisplatin chemotherapy in patients with unresectable stage III or IV NSCLC, intensifying chemotherapy by reducing the cycle length.
  • The second study used cyclophosphamide, doxorubicin, vincristine, and prednisone, CHOP chemotherapy, in the treatment of stage II-IV intermediate or immunoblastic high-grade lymphoma, intensifying chemotherapy first by reducing the cycle length and then by escalating the dosages of cyclophosphamide and doxorubicin.
  • Fifty-five patients with NSCLC and 49 with non-Hodgkin's lymphoma (NHL) were enrolled and treated in successive cohorts.
  • In the NSCLC trial, etoposide and cisplatin were intensified by >50%, and in the lymphoma trial, cyclophosphamide was intensified by 270% and doxorubicin was intensified by 87%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Recombinant Proteins. Thrombocytopenia / chemically induced. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709216.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone
  •  go-up   go-down


21. Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW: Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol; 2009 Nov 10;27(32):5390-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
  • PURPOSE: This multicenter, prospective, randomized controlled trial compared the efficacy and toxicity of two chemotherapy regimens in advanced Hodgkin's lymphoma (HL): the weekly alternating Stanford V and the standard, twice-weekly regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).
  • PATIENTS AND METHODS: Patients had stage IIB, III, or IV disease or had stages I to IIA disease with bulky disease or other adverse features.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Lung Diseases / chemically induced. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19738111.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN64141244
  • [Grant] United Kingdom / Cancer Research UK / / C2422/A2858
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


22. Guzicka-Kazimierczak R: [Primary gastric non-Hodgkin's lymphoma: clinical findings and prognostic factors]. Ann Acad Med Stetin; 2006;52(3):77-84; discussion 84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastric non-Hodgkin's lymphoma: clinical findings and prognostic factors].
  • PURPOSE: This work was undertaken to determine the clinical course and prognostic factors in patients with primary gastric non-Hodgkin's lymphoma (NHL).
  • A retrospective analysis was performed of the relationship between the outcome of treatment and age, gender, histological type of the lymphoma, clinical staging according to the original Ann Arbor classification and as modified by Stein and coworkers, functional status according to the ECOG scale, International Prognostic Index, type of lymphoma according to the classification of Kramer, and type of primary therapy.
  • The clinical picture of primary gastric non-Hodgkin's lymphoma is unrevealing.
  • Clinical symptoms are rarely typical of a systemic disease.
  • 2. Age, gender, functional status, histological type of the lymphoma, and clinical stage do not correlate with treatment outcome and survival.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Antineoplastic Agents / therapeutic use. Female. Gastrectomy. Humans. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17385352.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Sun XF, Zhen ZJ, Lui DG, Xia Y, He YJ, Wang ZH, Lin JY, Guan ZZ: Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol. Eur J Haematol; 2006 Nov;77(5):365-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol.
  • OBJECTIVES: This study was designed to evaluate the efficacy and toxicity of the modified B-Non-Hodgkin's Lymphoma (NHL)-Berlin-Frankfurt-Münster (BFM)-90-based protocol in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma.
  • The patients were stratified by risk factors (stage, LDH level and chemotherapy response).
  • Of these patients, 22 (40%) had Burkitt's lymphoma (BKL), 22 (40%) had diffuse large B-cell lymphoma (DLBL) and 11 (20%) had anaplastic large T-cell lymphoma (ALCL).
  • Complete remission (CR) occurred in 45 patients (83%), partial remission (PR) in eight patients (14.5%), and progressive disease (PD) in one patient (1.8%).
  • At a median follow up of 24 months, the event free survival (EFS) for all patients was 85% +/- 5% with 100% for group R1, 84% +/- 7% for group R2 and 72% +/- 13% for group R3, and most notably, 80% +/- 6% for stage III/IV at diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child. Child, Preschool. China. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Mucositis / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879606.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


24. Sun XF, Liu DG, Zhen ZJ, Chen XQ, Xia Y, Wang ZH, He YJ, Guan ZG: [Efficacy of short-term and intensive chemotherapy for the treatment of childhood and adolescent B cell non-Hodgkin's lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2005 Oct;26(10):581-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of short-term and intensive chemotherapy for the treatment of childhood and adolescent B cell non-Hodgkin's lymphoma].
  • OBJECTIVES: To evaluate the efficacy and toxicity of the B-NHL-BFM-90 protocol in the treatment of Chinese childhood and adolescent B-cell non-Hodgkin's lymphomas (B-NHL).
  • Of them 18 cases were Burkitt's lymphoma, 16 diffuse large B cell lymphoma and 8 anaplastic lymphoma.
  • There were 10 cases in stage II and 32 in stage III/IV.
  • Of the 5 PR patients, I received autologous hematopoietic stem cell transplantation, 3 received radiotherapy for residual disease and 1 just under watching.
  • 24%, being 100% for stage II and 80.95% for stage III/IV.
  • CONCLUSION: Short term and intensive chemotherapy can improves the efficacy and survival rate of childhood and adolescent B-NHL, especially for advanced stage patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Feasibility Studies. Female. Follow-Up Studies. Humans. Infant. Male. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16532964.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Lee JL, Kim MK, Lee KH, Hyun MS, Chung HS, Kim DS, Shin SO, Cho HS, Bae SH, Ryoo HM: Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol; 2005 Jan;84(1):13-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-Hodgkin's lymphomas of the orbit and ocular adnexa (OOA), the majority of which are extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type (MALT lymphomas), are a rare disorder.
  • The aim of this study was to evaluate the clinical features and treatment outcomes and complications in patients with MALT lymphoma of OOA.
  • Thirty-seven patients with a histologically verified diagnosis of MALT lymphoma of OOA were included in this retrospective, observational case study.
  • Combination chemotherapy alone was employed in three patients with stage IIIA(E) or IVA(E).
  • Subgroup analysis of the patients with localized disease, who received radiotherapy as an initial treatment modality, revealed that 3-year OS rate and EFS rate were 100% and 93%, respectively.
  • All disease recurrences were documented histologically as MALT lymphoma.
  • Radiotherapy alone can produce excellent local control and survival in patients with localized MALT lymphoma of OOA.
  • [MeSH-major] Eye Neoplasms. Lymphoma, B-Cell, Marginal Zone
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Orbital Neoplasms / complications. Orbital Neoplasms / pathology. Orbital Neoplasms / therapy. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15309523.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Yun J, Kim SJ, Kim JA, Kong JH, Lee SH, Kim K, Ko YH, Kim WS: Clinical features and treatment outcomes of non-Hodgkin's lymphomas involving rare extranodal sites: a single-center experience. Acta Haematol; 2010;123(1):48-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and treatment outcomes of non-Hodgkin's lymphomas involving rare extranodal sites: a single-center experience.
  • BACKGROUND: The involvement of certain organs such as the adrenal gland and ovaries is rare in non-Hodgkin's lymphoma (NHL).
  • Diffuse large B-cell lymphoma (DLBCL) was the most common (n = 39), and the median overall survival (OS) was 16.63 months.
  • The OS of DLBCL in rare extranodal sites was worse than that in common sites when compared based on tumor stage.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / therapy. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Kaplan-Meier Estimate. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / therapy. Prednisone / therapeutic use. Prognosis. Rituximab. Treatment Outcome. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 S. Karger AG, Basel.
  • (PMID = 19955711.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


27. Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ: [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2008 Aug;30(8):630-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
  • OBJECTIVE: To compare the efficacy of chemotherapy alone, radiotherapy alone and combined-modality therapy in the treatment for early-stage Hodgkin's lymphoma (HL).
  • METHODS: From 1999 to 2002, totally 150 patients with stage I or II HL were treated in our hospital.
  • RESULTS: The pathological types included nodular sclerosis (NS, n = 84), mixed-cellularity (MC, n = 39), lymphocyte-predominant (LP, n = 23), lymphocyte-depleted (LD, n = 3) and nodular lymphocyte predominant Hodgkin's disease (NLPHD, n = 1).
  • There were 33 patients with complete response (CR), 109 with partial response (PR), 5 with stable disease (SD) and 3 with progressive disease (PD) after initial therapy.
  • CONCLUSION: Combined-modality therapy is more effective than chemotherapy alone or radiotherapy alone in the treatment for early stage Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / chemically induced. Bleomycin / adverse effects. Bleomycin / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Dacarbazine / adverse effects. Dacarbazine / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Leukopenia / chemically induced. Male. Mechlorethamine / adverse effects. Mechlorethamine / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / adverse effects. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / therapeutic use. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Vinblastine / adverse effects. Vinblastine / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use. Young Adult


28. Landolsi A, Chabchoub I, Limem S, Gharbi O, Chaafai R, Hochlef M, Fatma LB, Trimech M, Krifa A, Ajmi S, Mokni M, Hadj Hmida MB, Ahmed SB: [Primary digestive tract lymphoma in central region of Tunisia: anatomoclinical study and therapeutic results about 153 cases]. Bull Cancer; 2010 Apr;97(4):435-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary digestive tract lymphoma in central region of Tunisia: anatomoclinical study and therapeutic results about 153 cases].
  • Primary gastro-intestinal lymphoma (PGIL) is the most common type of extra-nodal non Hodgkin's lymphoma.
  • In our country epidemiology of the disease is unknown with IPSID being the most frequent type.
  • Performance status (PS) < 2 was seen in 80% of patients, high grade lymphoma in 70.5% of cases and B phenotype was noted in 85%.
  • MALT lymphoma accounts for 50% of cases, and IPSID for only 5% of PGIL.
  • About 47.5% of cases were stage IE, 138 patients had chemotherapy with an objective response rate of 77%.
  • In high grade lymphoma patients favorable prognostic factors for OS included young age < or = 60 years, PS < 2, normal serum LDH, hemoglobin > 12 g/dL, B phenotype, localised stage (IE-IIE1), anthracycline-based chemotherapy regimen, achieving complete or partial response to induction chemotherapy and no relapse.
  • In low-grade lymphoma patients, none of these factors had a significant correlation with OS: age < or = 60 years, PS < 2, stage (IE-IIE1), response to induction chemotherapy, relapse.
  • They are more often high-grade, T phenotype and have locally advanced stage (IIE); surgery is more common in this group.
  • We conclude that stomach is the main site of PGIL in our region, intestinal lymphoma is less frequent and IPSID has become rare.
  • [MeSH-major] Gastrointestinal Neoplasms. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diarrhea / etiology. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Tunisia. Vomiting / etiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395189.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


29. Bence Z, Kovács G, Jakab Z, Csóka M, Müller J: [Lymphomas in adolescents: are childhood lymphoma therapy protocols suitable for this patient group?]. Magy Onkol; 2008 Dec;52(4):357-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphomas in adolescents: are childhood lymphoma therapy protocols suitable for this patient group?].
  • The centres of the Hungarian Paediatric Oncology Network annually take care of 250-300 new patients with childhood cancer, every tenth of them suffering from lymphoma.
  • The aim of our work was to analyse the data of the adolescents (14-19 years) with Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), comparing their survival rates with younger patients under fourteen and with the international data.
  • In the group of HL the distribution of patients according to the stage was similar in younger and older patients.
  • In the NHL group 55% of the children younger than 14, and 72% of the patients older than 14 years old had advanced stage disease (stage III or IV).
  • [MeSH-major] Aging. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / mortality. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adolescent. Age Distribution. Age Factors. Child. Child, Preschool. Female. Humans. Hungary / epidemiology. Infant. Male. Neoplasm Staging. Survival Analysis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068463.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


30. Ganti AK, Bociek RG, Bierman PJ, Enke CA, Vose JM, Armitage JO: Follicular lymphoma: expanding therapeutic options. Oncology (Williston Park); 2005 Feb;19(2):213-28; discussion 228, 233-6, 239
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular lymphoma: expanding therapeutic options.
  • The most common indolent lymphoma, follicular lymphoma comprises 35% of adult non-Hodgkin's lymphoma (NHL) in the United States and 22% worldwide.
  • Features associated with adverse outcome include age, male gender, disease stage, and performance status, with the International Prognostic Index being the most widely used risk classification system.
  • Long-term disease-free survival is possible in select patient subgroups after treatment, but very late relapses suggest that quiescent lymphoma cells might be harbored for long periods of time.
  • Radiation therapy is the mainstay of treatment for limited-stage follicular lymphoma, but there is some experience with chemotherapy and combined chemoradiation.
  • When to initiate treatment in patients with advanced disease is controversial, but options include various combined chemotherapy regimens, monoclonal antibodies, radiolabeled antibodies, and bone marrow or stem cell transplantation.
  • Future directions in the treatment of follicular lymphoma include vaccines, antisense therapy, and proteasome inhibitors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / radiotherapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770890.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cancer Vaccines; 0 / Oligonucleotides, Antisense; 0 / Proteasome Inhibitors
  • [Number-of-references] 148
  •  go-up   go-down


31. Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V: Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol; 2010 May 1;28(13):2239-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
  • PURPOSE: To determine whether epoetin alfa reduces anemia-related fatigue, improves other aspects of health-related patient-recorded outcomes (PROs), reduces the number of RBC transfusions, and has an impact on freedom from treatment failure (FFTF) and overall survival (OS) in patients with advanced-stage Hodgkin's lymphoma (HL).
  • PATIENTS AND METHODS: The prospectively randomized HD15EPO study performed by the German Hodgkin Study Group investigated epoetin alfa administered at doses of 40,000 U weekly during and after chemotherapy (six to eight cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone [BEACOPP]) in a double-blind, placebo-controlled setting.
  • CONCLUSION: Epoetin alfa administered at 40,000 U weekly parallel to BEACOPP chemotherapy was safe in patients with advanced-stage HL and reduced the number of RBC transfusions but had no impact on fatigue and other PRO domains.
  • [MeSH-major] Anemia / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Erythropoietin / therapeutic use. Hematinics / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Double-Blind Method. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Epoetin Alfa. Erythrocyte Transfusion. Etoposide / administration & dosage. Etoposide / adverse effects. Fatigue / drug therapy. Fatigue / etiology. Female. Germany. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Proportional Hazards Models. Prospective Studies. Recombinant Proteins. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. EPOETIN ALFA .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20368566.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hematinics; 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 11096-26-7 / Erythropoietin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 64FS3BFH5W / Epoetin Alfa; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; BEACOPP protocol
  •  go-up   go-down


32. Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD: Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol; 2008 Jan 10;26(2):204-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
  • This phase II multicenter study evaluated the efficacy and toxicity of bendamustine in patients with B-cell non-Hodgkin's lymphoma (NHL) refractory to rituximab.
  • RESULTS: Seventy-six patients, ages 38 to 84 years, with predominantly stage III/IV indolent (80%) or transformed (20%) disease were treated; 74 were assessable for response.
  • The median duration of response was 6.7 months (95% CI, 5.1 to 9.9 months), 9.0 months (95% CI, 5.8 to 16.7) for patients with indolent disease, and 2.3 months (95% CI, 1.7 to 5.1) for those with transformed disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Nitrogen Mustard Compounds / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Bendamustine Hydrochloride. Female. Humans. Male. Middle Aged. Rituximab. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2008 Apr 10;26(11) 1911
  • (PMID = 18182663.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-102216
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Nitrogen Mustard Compounds; 4F4X42SYQ6 / Rituximab; 981Y8SX18M / Bendamustine Hydrochloride
  •  go-up   go-down


33. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med; 2010 Mar 11;362(10):875-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.
  • BACKGROUND: Despite advances in treatments for Hodgkin's lymphoma, about 20% of patients still die from progressive disease.
  • METHODS: Using gene-expression profiling, we analyzed 130 frozen samples obtained from patients with classic Hodgkin's lymphoma during diagnostic lymph-node biopsy to determine which cellular signatures were correlated with treatment outcome.
  • In an independent cohort of patients, we found that an increased number of CD68+ macrophages was correlated with a shortened progression-free survival (P=0.03) and with an increased likelihood of relapse after autologous hematopoietic stem-cell transplantation (P=0.008), resulting in shortened disease-specific survival (P=0.003).
  • In multivariate analysis, this adverse prognostic factor outperformed the International Prognostic Score for disease-specific survival (P=0.003 vs. P=0.03).
  • The absence of an elevated number of CD68+ cells in patients with limited-stage disease defined a subgroup of patients with a long-term disease-specific survival of 100% with the use of current treatment strategies.
  • CONCLUSIONS: An increased number of tumor-associated macrophages was strongly associated with shortened survival in patients with classic Hodgkin's lymphoma and provides a new biomarker for risk stratification.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Massachusetts Medical Society
  • [Cites] Ann Oncol. 2006 Jan;17(1):110-6 [16291580.001]
  • [Cites] Immunol Rev. 2006 Apr;210:67-85 [16623765.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Blood. 2006 Jul 15;108(2):662-8 [16551964.001]
  • [Cites] Bone Marrow Transplant. 2007 Jan;39(1):41-7 [17115062.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3101-8 [17536082.001]
  • [Cites] J Surg Res. 2007 Sep;142(1):119-28 [17597158.001]
  • [Cites] Eur J Haematol. 2007 Nov;79(5):455-61 [17908180.001]
  • [Cites] Am J Clin Pathol. 2007 Dec;128(6):958-65 [18024321.001]
  • [Cites] Haematologica. 2008 Feb;93(2):193-200 [18223287.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1759-66 [18347177.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2765-3775 [19096012.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5920-6 [19188663.001]
  • [Cites] Oncogene. 2002 May 2;21(19):3095-102 [12082542.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):310-4 [12872350.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:225-47 [14633784.001]
  • [Cites] J Nutr. 2004 Apr;134(4):762-70 [15051823.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7 [15075390.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1478-84 [1383821.001]
  • [Cites] Ann Oncol. 1995 Nov;6(9):895-9 [8624292.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1467-73 [15746048.001]
  • [Cites] Blood. 2005 May 15;105(10):3979-86 [15677569.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3773-9 [15809450.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2005 Jun;27(6):957-68 [15943426.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Cell Immunol. 2005 May;235(1):21-8 [16165118.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1581-91 [16236613.001]
  • [CommentIn] N Engl J Med. 2010 Mar 11;362(10):942-3 [20220189.001]
  • [CommentIn] N Engl J Med. 2010 Jun 3;362(22):2135; author reply 2136 [20527079.001]
  • [CommentIn] N Engl J Med. 2010 Jun 3;362(22):2135-6; author reply 2136 [20527059.001]
  • [CommentIn] N Engl J Med. 2010 Jun 3;362(22):2135; author reply 2136 [20519687.001]
  • (PMID = 20220182.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; Canada / Canadian Institutes of Health Research / / 178536; United States / NCI NIH HHS / CA / U01 CA114778-05; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / U01-CA114778-01; United States / NCI NIH HHS / CA / CA114778-05; United States / NCI NIH HHS / CA / U01-CA 114778
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS194035; NLM/ PMC2897174
  •  go-up   go-down


34. Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Engert A, Borchmann P: Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). Haematologica; 2007 Apr;92(4):568-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018).
  • We conducted a two-stage phase II study to investigate the activity of bortezomib and dexamethasone in patients with relapsed Hodgkin's lymphoma.
  • The study was prematurely closed after the first stage with twelve enrolled patients because no response was observed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Boronic Acids / administration & dosage. Boronic Acids / adverse effects. Bortezomib. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Female. Humans. Male. Middle Aged. Pyrazines / administration & dosage. Pyrazines / adverse effects. Recurrence. Salvage Therapy. Treatment Failure

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488673.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00148018
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Letter; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


35. Han WS, Jung ES, Kim YH, Kim CH, Park SC, Lee JY, Chang YJ, Yeon JE, Byun KS, Lee CH: [Spontaneous resolution of vanishing bile duct syndrome in Hodgkin's lymphoma]. Korean J Hepatol; 2005 Jun;11(2):164-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spontaneous resolution of vanishing bile duct syndrome in Hodgkin's lymphoma].
  • Cholestasis in a patient with Hodgkin's disease is uncommon, and the causes of cholestasis are mainly direct tumor involvement of the liver, hepatotoxic effects of drugs, viral hepatitis, sepsis and opportunistic infections.
  • Vanishing bile duct syndrome (VBDS) represents a very rare cause for cholestasis in this disease.
  • We report here on a case of a 45-year-old man who developed VBDS during the complete remission stage of Hodgkin's lymphoma.
  • [MeSH-major] Bile Duct Diseases / complications. Bile Ducts, Intrahepatic. Cholestasis / complications. Hodgkin Disease / complications
  • [MeSH-minor] Adult. Humans. Male. Remission, Spontaneous

  • MedlinePlus Health Information. consumer health - Bile Duct Diseases.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15980675.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


36. Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, van't Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RW, Smit WG, Brice P, van Marwijk Kooy M, Baars JW, Poortmans P, Tirelli U, Leeksma OC, Tomsic R, Feugier P, Salles G, Gabarre J, Kersten MJ, Van Den Neste E, Creemers GJ, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Fermé C, Henry-Amar M, EORTC-GELA H8 Trial Group: Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol; 2009 Dec;10(12):1160-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.
  • BACKGROUND: Little is known about the longitudinal course of health-related quality of life (HRQoL) in patients with Hodgkin's lymphoma during their post-treatment follow-up and re-adaptation to normal life.
  • We report on the HRQoL of patients treated in the randomised H8 trial of the European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etudes des Lymphomes de l'Adulte (GELA).
  • INTERPRETATION: HRQoL data after treatment for early-stage Hodgkin's lymphoma show that patients experience strain and limitations in all subdomains apart from cognitive functioning (QLQ-C30), and also have reduced motivation (MFI-20).
  • [MeSH-major] Hodgkin Disease / psychology. Quality of Life
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Dec;10(12):1134-5 [19959071.001]
  • (PMID = 19828373.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00379041
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


37. Pavone V, Ricardi U, Luminari S, Gobbi P, Federico M, Baldini L, Iannitto E, Ucci G, Marcheselli L, Orsucci L, Angelucci E, Liberati M, Gavarotti P, Levis A, Intergruppo Italiano Linfomi (IIL): ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. Ann Oncol; 2008 Apr;19(4):763-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study.
  • BACKGROUND: In 1997, the Intergruppo Italiano Linfomi started a randomized trial to evaluate, in unfavorable stage IA and IIA Hodgkin's lymphoma (HL) patients, the efficacy and toxicity of the low toxic epirubicin, vinblastine and etoposide (EVE) regimen followed by involved field radiotherapy in comparison to the gold standard doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) regimen followed by the same radiotherapy program.
  • PATIENTS AND METHODS: Patients should be younger than 65 years with unfavorable stage IA and IIA HL (i.e. stage IA or IIA with bulky disease and/or subdiaphragmatic disease, erythrocyte sedimentation rate higher than 40, extranodal (E) involvement, hilar involvement and more than three involved lymph node areas).
  • CONCLUSIONS: In unfavorable stage IA and IIA HL patients, no differences were observed between ABVD and EVE arms in terms of CR rate and OS.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180244.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


38. Yun J, Kim SJ, Won JH, Choi CW, Eom HS, Kim JS, Kim MK, Kwak JY, Kim WS, Suh C: Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. Leuk Res; 2010 Sep;34(9):1175-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report.
  • Fourteen patients had primary ovarian lymphoma, while eighteen patients had secondary ovarian involvement.
  • There was no significant difference in survival rates between primary and secondary involvement with diffuse large B-cell lymphoma (DLBCL), the most common subtype.
  • The localized bilateral ovarian involvement showed poorer survival compared to stage III/IV patients with secondary ovarian involvement.
  • Treatment outcomes of secondary ovarian involvement in non-Hodgkin's lymphoma were comparable to those of primary ovarian involvement, suggesting that ovarian involvement does not necessarily predict a worse prognosis for NHL patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206997.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


39. Norhany S, Kouzu Y, Uzawa K, Hayama M, Higo M, Koike H, Kasamatu A, Tanzawa H: Overexpression of PAX5 in oral carcinogenesis. Oncol Rep; 2006 Nov;16(5):1003-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The PAX5 gene is involved in medulloblastoma, non-Hodgkin's lymphoma, transitional cell carcinoma of the bladder, neuroblastoma, breast cancer and SCC.
  • The results suggest that PAX5 plays an important role during oral carcinogenesis, especially in the early stage, and that the gene may have potential as a biomarker and therapeutic target for OSCC.
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Female. Humans. Immunohistochemistry. Leukoplakia / genetics. Leukoplakia / metabolism. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17016584.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / RNA, Messenger
  •  go-up   go-down


40. Macann A, Bredenfeld H, Müller RP, Diehl V, Engert A, Eich HT: Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group. Int J Radiat Oncol Biol Phys; 2008 Jan 1;70(1):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group.
  • PURPOSE: To evaluate the effect of radiotherapy on the severe pulmonary toxicity observed in the pilot study of BAGCOPP (bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine) for advanced-stage Hodgkin's lymphoma.
  • METHODS AND MATERIALS: Patients with Stage III or IV Hodgkin's lymphoma or Stage IIB with risk factors participated in this single-arm, multicenter pilot study.
  • Gemcitabine (when administered without bleomycin) remains of interest in Hodgkin's lymphoma and is being incorporated into a new German Hodgkin's Lymphoma Study Group protocol that also includes consolidative radiotherapy.
  • This study supports the concept of the integration of radiotherapy in gemcitabine-containing regimens in Hodgkin's lymphoma if there is an interval of at least 4 weeks between the two modalities and with a schedule whereby radiotherapy follows the chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lung / drug effects. Lung / radiation effects
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Doxorubicin / administration & dosage. Drug Interactions. Etoposide / administration & dosage. Female. Germany. Humans. Male. Middle Aged. Pilot Projects. Prednisone / administration & dosage. Procarbazine / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17855012.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; VB0R961HZT / Prednisone; BEACOPP protocol
  •  go-up   go-down


41. Lee MY, Tan TD, Feng AC, Liu MC: Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institution. Am J Hematol; 2006 Aug;81(8):568-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median age at onset of disease was 56 years for B-cell lymphoma (BCL), 50 years for T/NK-cell lymphoma (TCL), and 26 years for Hodgkin's lymphoma (HL).
  • The major subtypes of non-HL were diffuse large B-cell lymphoma, follicular lymphoma, plasma cell myeloma, marginal zone lymphoma of mucosa-associated lymphoid tissue type, mantle cell lymphoma, unspecified peripheral TCL, and nasal type T/NK-cell lymphoma.
  • To the best of our knowledge, this is the largest series study of malignant lymphoma in Taiwan.
  • Immunophenotype, histological subtype, and clinical stage play significant roles in prognosis (P < 0.05).
  • [MeSH-major] Hodgkin Disease / mortality. Killer Cells, Natural / pathology. Lymphoma, B-Cell / mortality. Lymphoma, T-Cell / mortality
  • [MeSH-minor] Adult. Age Distribution. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Sex Distribution. Survival Rate. Taiwan / epidemiology. World Health Organization

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16823825.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A, Horwich A: Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol; 2008 Jul;19(7):1312-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
  • BACKGROUND: The purpose of this study was to assess prognostic factors and outcome of patients with relapsed/refractory Hodgkin's lymphoma (HL) who received high-dose chemotherapy and autologous stem-cell transplant (ASCT).
  • Demography at ASCT was 61% stage IV, median age 31 years (18-69), median prior treatment (tx) regimens 3 (2-7), median Hasenclever index 3 (0-6); 150 patients had responding disease [54 complete remission (CR), 96 partial remission (PR)], and 45 patients had untested relapse/refractory disease.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18356139.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


43. Barzilai A, Trau H, David M, Feinmesser M, Bergman R, Shpiro D, Schiby G, Rosenblatt K, Or R, Hodak E: Mycosis fungoides associated with B-cell malignancies. Br J Dermatol; 2006 Aug;155(2):379-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The coexistence of mycosis fungoides, a peripheral T-cell lymphoma, and B-cell malignancies or Hodgkin's lymphoma in the same patient is unusual.
  • OBJECTIVES: To detect cases of mycosis fungoides associated with B-cell malignancies or Hodgkin's lymphoma and to analyse the characteristics of and the interplay between the lymphoproliferative neoplasms.
  • METHODS: Patients with mycosis fungoides who had B-cell malignancies or Hodgkin's lymphoma were selected from among 398 patients either treated or followed up in two tertiary medical centres during a 7-year period.
  • RESULTS: Eleven patients with mycosis fungoides and B-cell malignancy were detected (seven of non-Hodgkin's lymphoma, three of chronic lymphocytic leukaemia, one of multiple myeloma).
  • No case of Hodgkin's lymphoma was found.
  • Two patients who presented with early-stage mycosis fungoides (IA) as the first lymphoma developed mycosis fungoides tumours after becoming immunosuppressed.
  • One showed two distinct populations of the malignant cells in the skin tumour, thus constituting a classical composite lymphoma of mycosis fungoides and chronic lymphocytic leukaemia, while in the other patient the two malignant populations of marginal B-cell lymphoma and mycosis fungoides (as evidenced by both phenotypic and genotypic findings) were intermingled.
  • CONCLUSIONS: This case series indicates that while the coexistence of Hodgkin's lymphoma and mycosis fungoides is extremely rare, the association of mycosis fungoides and B-cell malignancies is not as rare as reflected in the literature, with non-Hodgkin's lymphoma constituting the most common associated B-cell malignancy.
  • It is suggested that for greater precision the criteria for diagnosis of composite lymphoma of the skin should include both phenotypic and genotypic features.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Mycosis Fungoides / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hodgkin Disease / pathology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, T-Cell, Peripheral / pathology. Male. Middle Aged


44. Dodge JL, Mills PK, Riordan DG: Cancer survival in California Hispanic farmworkers, 1988-2001. J Rural Health; 2007;23(1):33-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cox proportional hazards models for the most common cancers provided age-, stage-, and year of diagnosis-adjusted hazard ratios.
  • FINDINGS: Observed 5-year cancer-specific survival rates were lower for Hispanic United Farm Workers of America men compared to California Hispanic men for all cancer sites combined (53.7% vs 57.7%, respectively) and colorectal cancer (48.1% vs 60.6%, respectively) and higher for non-Hodgkin's lymphoma (86.7% vs 57.6%, respectively).
  • Only non-Hodgkin's lymphoma survival differences remained significant (P = .021) after adjusting for age and stage at diagnosis.
  • Histology-specific analyses with larger sample sizes are required before reaching conclusions on non-Hodgkin's lymphoma survival differences.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. California / epidemiology. Humans. Male. Medical Records / statistics & numerical data. Middle Aged. Neoplasm Staging. Primary Health Care / organization & administration. Proportional Hazards Models. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • MedlinePlus Health Information. consumer health - Rural Health Concerns.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300476.001).
  • [ISSN] 0890-765X
  • [Journal-full-title] The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association
  • [ISO-abbreviation] J Rural Health
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5R01 CA101181; United States / PHS HHS / / U55/ CCR921930-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


45. Lim ST, Fei G, Quek R, Lim LC, Lee LH, Yap SP, Loong S, Tao M: The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol; 2007 Aug;79(2):132-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis.
  • AIM OF THE STUDY: This study aims to evaluate the association between hepatitis B virus (HBV) and lymphoma and to characterize HBV-related lymphomas.
  • METHODS: We compared the prevalence rate of HBV infection in 556 patients with lymphoma seen over a 4-yr period with that in a group of 4698 Singapore residents aged 18-69 who participated in the National Health Survey.
  • Next, we compared the clinic-pathologic characteristics of HBV-positive and HBV-negative lymphoma cases.
  • An association was observed for non-Hodgkin's lymphoma (NHL) but not Hodgkin's lymphoma.
  • The characteristics of HBV-infected patients with lymphoma were similar to those who were HBV-uninfected in terms of age, ECOG, extra-nodal involvement, LDH level, stage, complete remission rate and overall survival.
  • [MeSH-major] Hepatitis B / complications. Hepatitis B / pathology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anthracyclines / therapeutic use. Drug Therapy, Combination. Female. Humans. Lamivudine / therapeutic use. Male. Middle Aged. Prevalence. Prognosis. Steroids / therapeutic use. Survival Rate

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17635237.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Steroids; 2T8Q726O95 / Lamivudine
  •  go-up   go-down


46. Boleti E, Mead GM: ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol; 2007 Feb;18(2):376-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors.
  • BACKGROUND: We investigated whether administration of full-dose ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy without growth factors, and irrespective of the granulocyte count, caused treatment delays or increased the number of infective episodes, in patients with Hodgkin's lymphoma (HL).
  • PATIENTS AND METHODS: Thirty-eight patients with confirmed predominantly early-stage HL were treated with ABVD outside clinical trial protocols over a 5-year period on an outpatient basis.
  • All patients are currently disease-free, although three (7.8%) required salvage high-dose therapy (one relapsed and two with refractory disease).

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071938.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


47. Poirel HA, Cairo MS, Heerema NA, Swansbury J, Aupérin A, Launay E, Sanger WG, Talley P, Perkins SL, Raphaël M, McCarthy K, Sposto R, Gerrard M, Bernheim A, Patte C, FAB/LMB 96 International Study Committee: Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia; 2009 Feb;23(2):323-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.
  • Clinical studies showed that advanced stage, high LDH, poor response to reduction therapy and combined bone marrow and central nervous system disease are significantly associated with a decreased event-free survival (EFS) in pediatric mature B-cell non-Hodgkin's lymphoma (B-NHL) treated on FAB/LMB96.
  • Although rearranged MYC/8q24 (R8q24) is characteristic of Burkitt lymphoma (BL), little information is available on other cytogenetic abnormalities and their prognostic importance.
  • We performed an international review of 238 abnormal karyotypes in childhood mature B-NHL treated on FAB/LMB96: 76% BL, 8% Burkitt-like lymphoma, 13% diffuse large B-cell lymphoma (DLBCL).
  • Incidence of R8q24 (34%) was higher than reported in adult DLBCL.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Semin Cancer Biol. 2002 Oct;12(5):381-7 [12191637.001]
  • [Cites] Leukemia. 2003 Oct;17(10):2016-24 [14513052.001]
  • [Cites] Leukemia. 2004 Mar;18(3):584-8 [14712292.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Mar;26(3):169-78 [15125609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Ann Genet. 1989;32(1):26-32 [2751244.001]
  • [Cites] Genes Chromosomes Cancer. 1989 Nov;1(2):115-8 [2487150.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jun;60(2):206-9 [1606568.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3905-14 [7579360.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):1-19 [9720711.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):3015-23 [15728515.001]
  • [Cites] Pediatr Blood Cancer. 2005 Oct 15;45(5):616-22 [16127683.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):840-7 [18371107.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):510-18 [10653866.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):47-51 [10690386.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):1099-106 [11697627.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Sep;153(2):115-21 [15350300.001]
  • [Cites] Int J Cancer. 1976 Jan 15;17(1):47-56 [946170.001]
  • [Cites] Cancer Genet Cytogenet. 1981 Jun;3(4):307-15 [7260888.001]
  • [Cites] Nature. 1982 Jul 29;298(5873):474-6 [6806672.001]
  • [Cites] Cell. 1983 Oct;34(3):779-87 [6414718.001]
  • [Cites] C R Acad Sci III. 1984;298(6):143-5 [6324967.001]
  • [Cites] IARC Sci Publ. 1985;(60):65-80 [2998996.001]
  • (PMID = 19020548.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098543-06; United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS107551; NLM/ PMC2988438
  • [Investigator] Avet-Loiseau H; Baranger L; Barin C; Bastard C; Bernheim A; Berthéas MF; Bilhou-Nabera C; Borie C; Caillet-Bauchu E; Capdano AM; Collonge-Rame MA; Cornillet P; Couturier J; Dastugue N; Daudignon A; Gachard N; Grégoire MJ; Heimann P; Henry C; Laï JL; Leroux D; Lessard M; Luquet I; Mellink CH; Nadal N; Pagès MP; Penther D; Perissel B; Raynaud S; Talman P; Taviaux S; Tigaud I; Van den Akker J; Beigel J; Benn P; Cantu E; Carlson K; Cooley L; Dawson A; Dev VG; Dewald G; Drumheller T; Fink J; Gadi I; Hanna J; Glassman A; Harrison K; Heerema N; Higgins J; Higgins R; Hirsch B; Horsman D; Kalousek D; Koduru P; Lebo R; Li X; Magenis RE; McFadden K; McGavron L; McMorrow L; Murch A; Opheim K; Panzar D; Pasztor L; Pettigrew A; Philips C; Rao K; Rao PN; Rouston D; Sanger W; Satya-Prakash KL; Schwartz S; Sekhon GS; Shaw G; Shekter-Levin S; Spinner N; Stanley W; Storto P; Thangavelu M; Theil K; Vance G; VanDyke D; Zadeh T; Andrews K; Booth M; Bown N; Davies T; Grace E; Griffiths M; Howard P; Hughes D; Kempski H; Lillington D; Lowther G; Martin K; Roberts P; Ross F; Sadler J; Stallings R; Stevenson D; Swansbury J; Talley P; Telford N; Walker H
  •  go-up   go-down


48. Adams MJ, Constine LS, Lipshultz SE: Late effects of therapy for Hodgkin's lymphoma. Curr Hematol Malig Rep; 2007 Jul;2(3):143-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late effects of therapy for Hodgkin's lymphoma.
  • Hodgkin's lymphoma exemplifies a malignancy in which the benefits and risks of therapy are strikingly obvious: although 70% to 95% of patients survive (depending on disease stage), the late adverse health effects of therapy compromise quality of life and can be fatal.
  • Although secondary malignancies and cardiovascular disease are the most life-threatening sequelae, pulmonary, endocrine, and reproductive effects can also substantially compromise quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cardiovascular Diseases / etiology. Hodgkin Disease / therapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Anthracyclines / administration & dosage. Anthracyclines / adverse effects. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Fatigue / etiology. Female. Humans. Hypothyroidism / epidemiology. Hypothyroidism / etiology. Infertility / epidemiology. Infertility / etiology. Leukemia, Radiation-Induced / epidemiology. Leukemia, Radiation-Induced / etiology. Male. Quality of Life. Radiation Pneumonitis / epidemiology. Radiation Pneumonitis / etiology. Risk. Survivors. Time Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3226-33 [11432890.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):480-4 [7640236.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2794-801 [16996260.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Mar;4(3):249-57 [16507272.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1428-37 [16204692.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3358-65 [16051739.001]
  • [Cites] Pediatr Blood Cancer. 2005 Oct 15;45(5):700-5 [15926158.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1203-10 [9070499.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1241-7 [1739922.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jun 15;44(7):600-6 [15856486.001]
  • [Cites] Radiother Oncol. 1999 Apr;51(1):35-42 [10386715.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1723-8 [16492690.001]
  • [Cites] N Engl J Med. 1996 Mar 21;334(12):745-51 [8592547.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3484-94 [12177110.001]
  • [Cites] Semin Radiat Oncol. 1996 Jul;6(3):225-242 [10717180.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):169-79 [10924987.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1878-86 [17119114.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):253-61 [10458240.001]
  • [Cites] JAMA. 2003 Jul 23;290(4):465-75 [12876089.001]
  • [Cites] JAMA. 1993 Oct 27;270(16):1949-55 [8411552.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6587-95 [16170166.001]
  • [Cites] Am J Clin Oncol. 2004 Feb;27(1):73-80 [14758137.001]
  • [Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7555-64 [16234521.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7614-20 [16186594.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 7;99(3):206-14 [17284715.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5735-41 [17179107.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):332-7 [17235049.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):43-9 [17194904.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1516-21 [16575001.001]
  • [Cites] Am Heart J. 2005 Nov;150(5):977-82 [16290974.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 2;95(13):971-80 [12837833.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1208-15 [8315419.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6508-15 [16170160.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1949-55 [16227316.001]
  • [Cites] J Clin Oncol. 1994 Feb;12(2):297-305 [7509383.001]
  • [Cites] Tumori. 2006 Jul-Aug;92 (4):295-8 [17036519.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3139-48 [15284266.001]
  • [Cites] Ann Intern Med. 2004 Oct 19;141(8):590-7 [15492338.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):487-97 [10653864.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89 [17392385.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3431-9 [12885835.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):890-6 [16818852.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):327-33 [16377179.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4386-94 [14645429.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1989-96 [12200357.001]
  • [Cites] Cancer J Sci Am. 1995 May-Jun;1(1):33-42 [9166452.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 6;85(1):25-31 [8416252.001]
  • (PMID = 20425363.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents, Alkylating
  • [Number-of-references] 52
  •  go-up   go-down


49. Kahn ST, Flowers CR, Lechowicz MJ, Hollenbach K, Johnstone PA: Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients. Cancer J; 2005 Sep-Oct;11(5):425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
  • This study assessed efficacy, optimal dosage and timing, and toxicity of involved-field radiotherapy used in conjunction with high-dose chemotherapy and stem cell transplantation for patients with refractory/relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
  • METHODS AND MATERIALS: 306 patients with refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma were analyzed.
  • Thirty-three patients received involved-field radiotherapy prior to stem cell transplantation directed at symptomatic and/or bulky sites; eight patients received involved-field radiotherapy after stem cell transplantation directed at sites of persistent disease.
  • The other 265 patients with refractory/relapsed non-Hodgkin's lymphoma and Hodgkin's disease received high-dose chemotherapy/stem cell transplantation, but not involved-field radiotherapy.
  • Multivariate analysis found that patients who did not receive involved-field radiotherapy were 2.09 times more likely to die during the follow-up period than patients who received involved-field radiotherapy (P = 0.066; adjusted for age, stem cell transplantation type, stage I/II vs stage III/IV, refractory vs relapsed, and Hodgkin's disease vs non-Hodgkin's lymphoma).
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Female. Follow-Up Studies. Humans. Male. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pelvic Neoplasms / pathology. Pelvic Neoplasms / therapy. Proportional Hazards Models. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Retrospective Studies. Splenic Neoplasms / pathology. Splenic Neoplasms / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259874.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Kidmas AT, Ugwu BT, Manasseh AN, Iya D, Opaluwa AS: Male breast malignancy in Jos University Teaching Hospital. West Afr J Med; 2005 Jan-Mar;24(1):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five (19.2%) were stage II; 15(57.7%) stage III and 6(23.1%) stage IV.
  • There were 23 (88.5%) carcinomas, 2 (7.7%) fibrosarcomas and a case of Hodgkin's lymphoma.
  • Simple mastectomy was done in 13 (50%) as toilet procedures for advanced disease.
  • The only case of Hodgkin's lymphoma had chemotherapy.
  • Late presentation with advanced disease and ulceration is a common feature in our environment.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Hospitals, Teaching / utilization. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Nigeria / epidemiology. Patient Acceptance of Health Care. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909708.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


51. Ko OB, Lee DH, Kim SW, Lee JS, Kim S, Huh J, Suh C: Clinicopathologic characteristics of T-cell non-Hodgkin's lymphoma: a single institution experience. Korean J Intern Med; 2009 Jun;24(2):128-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics of T-cell non-Hodgkin's lymphoma: a single institution experience.
  • BACKGROUND/AIMS: Although the incidence of T-cell non-Hodgkin's lymphoma (NHL) is higher in Far East Asia than in Western countries, its incidence and clinical course in Korea are not well-defined.
  • The most frequent subtypes of T-cell NHL were extranodal NK/T-cell lymphoma, nasal type (NASAL), peripheral T-cell lymphoma, unspecified type (PTCL-U), and anaplastic large cell lymphoma, T/null cell, primary systemic type (ALCL).
  • Univariate analysis of IPI elements and other clinical features showed that clinical stage and extranodal sites were significant predictors of survival.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. Female. Humans. Incidence. Kaplan-Meier Estimate. Korea / epidemiology. Male. Middle Aged. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Oct;5(5):983-1001 [1938764.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):923-30 [9378552.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2439-48 [9635538.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):1-12 [15480663.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2797-804 [15728226.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1255-64 [16210342.001]
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Sep;15(3):533-47 [12468404.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Hum Pathol. 1983 Sep;14(9):745-72 [6350154.001]
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):143-8 [6381328.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Apr;21(4):487-92 [4007017.001]
  • [Cites] Jpn J Clin Oncol. 1985 Sep;15(3):517-35 [2997510.001]
  • [Cites] Jpn J Clin Oncol. 1985 Dec;15(4):645-51 [4094097.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):370-80 [8001008.001]
  • (PMID = 19543491.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2698621
  • [Keywords] NOTNLM ; Lymphoma / Peripheral / T-cell
  •  go-up   go-down


52. Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J: Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm; 2007 May;13(4):337-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To (1) describe the use of pegfilgrastim and filgrastim in oncology practices throughout the United States and (2) compare their effectiveness in actual practice as measured by the outcome of febrile neutropenia in patients who received chemotherapy regimens administered every 3 to 4 weeks for breast, lung, ovarian, colon cancer, or lymphoma and who received a CSF prior to developing FN.
  • METHODS: Data were retrospectively obtained from the medical records of a cohort of adult patients aged 18 years or older treated in 99 community oncology practices in the United States in 2001 and 2003.
  • Eligible patients were treated with chemotherapy every 3 to 4 weeks for breast, lung, ovarian, colon cancer, or lymphoma and were users of filgrastim in 2001 (prior to the U.S.
  • Patients who received pegfilgrastim were more likely to have at least 1 myelosuppressive drug (74.8%) in the regimen compared with patients who received filgrastim in 2003 (70.0%, P = 0.013), but a greater proportion of filgrastim patients in 2003 (19.4%) had advanced-stage disease compared with pegfilgrastim patients (14.8%, P = 0.005).
  • More patients who received filgrastim in 2003 (36.2%) had a cancer other than breast cancer or non-Hodgkin's lymphoma compared with those who received pegfilgrastim (29.5%, P = 0.001).

  • MedlinePlus Health Information. consumer health - Fever.
  • Hazardous Substances Data Bank. Filgrastim .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506600.001).
  • [ISSN] 1083-4087
  • [Journal-full-title] Journal of managed care pharmacy : JMCP
  • [ISO-abbreviation] J Manag Care Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


53. He YF, Li YH, Huang HQ, Xia ZJ, Sun XF, Lin TY, Lin XB, Yuan ZY, Li ZM, Wang FH, Wang SS, Jiang WQ: [Clinical analysis of 59 cases of primary gastric non-Hodgkin's lymphoma]. Ai Zheng; 2005 Apr;24(4):475-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 59 cases of primary gastric non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: Gastrointestinal tract is the most common extranodal involvement site of non-Hodgkin's lymphoma (NHL).
  • RESULTS: Of the 59 PGNHL patients, 46 (78.0%) were in stage I/II.
  • For those patients in intermediate grade (including immunoblastic cell lymphoma), there was no significant difference in the 5-year survival rate between the patients received chemotherapy plus surgery and the patients received chemotherapy alone (52.5% vs. 57.1%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820073.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


54. Karchenko VP, Voznyĭ EK, Belonogov AV, Bozhenko VK, Olfer'ev MA, Galil-Ogly GA: [Monoclonal antibody therapy with mabtera of patients with b-cell low grade non-Hodgkin's lymphoma]. Vopr Onkol; 2005;51(1):60-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Monoclonal antibody therapy with mabtera of patients with b-cell low grade non-Hodgkin's lymphoma].
  • The data on monoclonal antibody monotherapy (mabtera, rituximab) in 44 patients with B-cell low grade non-Hodgkin's lymphoma were assessed.
  • Fever and shivering stage I and II were among the most frequent post-infusion effects.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Dose-Response Relationship, Immunologic. Humans. Middle Aged. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909809.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


55. El Weshi A, Akhtar S, Mourad WA, Ajarim D, Abdelsalm M, Khafaga Y, Bazarbashi S, Maghfoor I: T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Leuk Lymphoma; 2007 Sep;48(9):1764-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature.
  • T-cell/histiocyte-rich B-cell lymphoma (TC/HRBCL) is a rare subtype of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with characteristic morphologic and immunophenotypic features, often misdiagnosed as Hodgkin's lymphoma and peripheral T-cell lymphoma.
  • We retrospectively reviewed all patients diagnosed and managed at our institution between 1995 and 2004 diagnosed with T-cell-rich-B-cell lymphoma by WHO criteria.
  • Stage distribution was I - II in 21 patients, and III - IV in 40.
  • Fifty-two percent of patients (32) had splenic involvement and thirty-seven patients (61%) presented with extranodal disease (22 >or= 2 sites).
  • At a median follow-up of 22 months (range 1 - 132); 32 patients (52%) are alive with no evidence of disease.
  • It has an aggressive course and poor outcome; with most of patients presenting with advanced disease stage together with high IPI score.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Salvage Therapy. Treatment Failure

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Sep;48(9):1670-1 [17786700.001]
  • (PMID = 17786712.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 31
  •  go-up   go-down


56. Sanna G, Lorizzo K, Rotmensz N, Bagnardi V, Cinieri S, Colleoni M, Nolè F, Goldhirsch A: Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors. Ann Oncol; 2007 Feb;18(2):288-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors.
  • BACKGROUND: Better therapeutic approaches for patients with Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL) resulted in high cure rates, at cost of serious late side effects.
  • Second primary tumours are a major concern for long-term survivors, and breast cancer (BC) is the most common solid tumour among women treated for HD.
  • MATERIALS AND METHODS: Fifty-three women treated for primary BC with previous history of malignant lymphoma were identified in our institution, 35 with HD (66%), 18 (34%) with NHL.
  • A comparison group was randomly selected from our database matching for each patient with previous lymphoma, two patients with primary BC (rate 1 : 2) for age, stage (pathological tumour size [pT] status and nodal status), year of diagnosis, and estrogen and progesterone status (positive versus negative).
  • The primary end points were disease-free survival (DFS) and overall survival (OS).
  • Considering these variables, no significant differences were observed between the two groups with the exception of Ki-67, which was found higher in those with previous HD or NHL (65% versus 49%, respectively, P = 0.0526, borderline significant).
  • However, regarding patients with node-positive disease (14 versus 35 patients), five patients in the lymphoma group (36%), compared with 24 (69%) in the matched group received anthracycline-based therapy (P = 0.0345).
  • CONCLUSIONS: Previous history of malignant lymphoma is a negative prognostic factor for women diagnosed subsequently with BC.
  • Influence of other variables, like previous exposure to cytotoxics, or some unknown biological features related to the previous disease and treatment, should still be investigated in the attempt to improve the dire outcome of these patients.


57. Mounier N, Fermé C: [Particularities of Hodgkin's lymphoma]. Rev Prat; 2010 Jan 20;60(1):75-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Particularities of Hodgkin's lymphoma].
  • [Transliterated title] Particularités du lymphome de Hodgkin.
  • A risk-adapted strategy for adult patients with Hodgkin's lymphoma is based on risk factors at diagnosis.
  • First line chemotherapy with the gold standard ABVD regimen, with 3 or 4 courses for patients without or with risk factors, respectively, followed by radiation therapy targeting the initially affected areas (involved-field RT), at a dose of 30 Gy, is the treatment of choice for all early-stage supradiaphragmatic disease.
  • Treatment for disseminated disease is based on chemotherapy alone.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20222316.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


58. Salaun PY, Gastinne T, Bodet-Milin C, Campion L, Cambefort P, Moreau A, Le Gouill S, Berthou C, Moreau P, Kraeber-Bodéré F: Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging; 2009 Nov;36(11):1813-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?
  • PURPOSE: (18)F-FDG PET has been successfully evaluated in the management of Hodgkin's lymphoma (HL) and the most recent international guidelines recommended (18)F-FDG PET for initial staging and final therapeutic assessment.
  • These data were compared with the patient's characteristics including sex, age, Ann Arbor staging, bulky disease (tumour burden > 10 cm), presence of B symptoms, bone foci on PET (n = 106), bone marrow involvement (BMI) on biopsy (n = 75), leukocyte count (n = 74), lactic dehydrogenase (LDH) (n = 87), C-reactive protein (CRP) (n = 83) and fibrinogen (n = 60).
  • For semi-quantitative BMU evaluation, multivariate analysis found an independent correlation between sacral SUVs and CRP level (p = 0.032) and Ann Arbor stage (p = 0.005).
  • CONCLUSION: Our study demonstrates that diffuse BMU at initial staging of HL could be due to bone marrow involvement but more likely to bone marrow inflammatory change and that diffuse SU in contrast is probably more associated with disease involvement than with inflammatory change.
  • [MeSH-major] Bone Marrow / metabolism. Diffusion. Fluorodeoxyglucose F18 / metabolism. Hodgkin Disease / metabolism. Hodgkin Disease / pathology. Inflammation / complications. Spleen / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2002 Aug;43(8):1018-27 [12163626.001]
  • [Cites] Ann Oncol. 2000 Nov;11(11):1405-11 [11142480.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):958-63 [15937306.001]
  • [Cites] Ann Intern Med. 1975 Mar;82(3):365-6 [1172924.001]
  • [Cites] Gastroenterol J. 1990;50(3):117-23 [2288652.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1995;7(5):334-5 [8580066.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):173-80 [9440740.001]
  • [Cites] Med Pediatr Oncol. 1989;17(5):418-23 [2796857.001]
  • [Cites] J Cancer Res Clin Oncol. 1985;110(1):65-70 [2410428.001]
  • [Cites] Ann Hematol. 2003 Jul;82(7):390-6 [12764547.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1460-6 [8620424.001]
  • [Cites] Ann Surg. 1985 Apr;201(4):465-9 [3977447.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):93-9 [8270463.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):603-9 [9469348.001]
  • [Cites] Pathology. 1979 Jan;11(1):53-7 [431979.001]
  • [Cites] Clin Radiol. 1994 Mar;49(3):149-61 [8143402.001]
  • [Cites] Eur J Radiol. 2008 May;66(2):325-31 [17651934.001]
  • [Cites] Rev Esp Med Nucl. 2005 Mar-Apr;24(2):107-12 [15745681.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):60-7 [17021808.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1522-31 [11920510.001]
  • [Cites] Radiology. 1994 Jan;190(1):111-6 [8259386.001]
  • [Cites] Blood. 2007 Nov 15;110(10 ):3507-16 [17709603.001]
  • [Cites] Leuk Lymphoma. 2008 Apr;49(4):719-26 [18398739.001]
  • [Cites] Ann Oncol. 1999 Nov;10(11):1343-8 [10631463.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:259-65, 510-1 [17124070.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):885-94 [6378359.001]
  • [Cites] Hematol Pathol. 1989;3(1):29-33 [2745358.001]
  • [Cites] Recent Results Cancer Res. 2000;156:78-89 [10802866.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] J Nucl Med. 1997 Mar;38(3):343-8 [9074514.001]
  • [Cites] Blood. 1998 May 1;91(9):3340-6 [9558391.001]
  • [Cites] J Clin Pathol. 1990 Aug;43(8):630-2 [2401730.001]
  • [Cites] Eur J Nucl Med. 1998 Jul;25(7):721-8 [9662594.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):686-91 [2013808.001]
  • [Cites] Tumori. 1995 Nov-Dec;81(6):410-3 [8804465.001]
  • (PMID = 19499219.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


59. Ngeow JY, Quek RH, Ng DC, Hee SW, Tao M, Lim LC, Tan YH, Lim ST: High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol; 2009 Sep;20(9):1543-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
  • BACKGROUND: Data assessing the role of positron emission tomography (PET)/computed tomography (CT) imaging in lymphoma staging is still being accumulated and current staging is based primarily on CT.
  • This study aims to compare the value of PET/CT over conventional CT and bone marrow biopsy (BMB) in the initial evaluation of patients with lymphoma.
  • RESULTS: Among the 122 patients, 101 had non-Hodgkin's lymphoma (NHL) and 21 had Hodgkin's lymphoma (HL).
  • Compared with conventional CT, PET/CT upstaged 21 (17%) cases [B-cell non-Hodgkin's lymphoma (B-NHL), 12; T-cell non-Hodgkin's lymphoma (T-NHL), 3; HL, 6].
  • Of note, all 13 with early-stage HL had negative PET/CT scan and BMB.
  • In patients with aggressive B-NHL, BMB and PET/CT agreed in 58 patients (92%) and disagreed in five (8%), while the corresponding rates in indolent B-cell lymphoma were 14 (67%) and seven patients (33%), respectively.
  • This is particularly true of early-stage HL, suggesting that BMB may be safely omitted in this group.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474116.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


60. Barta SK, Yahalom J, Shia J, Hamlin PA: Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma. Clin Lymphoma Myeloma; 2006 Jul;7(1):77-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma.
  • Paraneoplastic cholestasis is an uncommon presenting symptom in Hodgkin's lymphoma (HL).
  • We report a patient with idiopathic cholestasis and early-stage HL with favorable risk factors whose liver biopsy results were consistent with intrahepatic cholestasis and no ductopenia.
  • The distinction between these 2 diseases has prognostic implications: idiopathic cholestasis is usually reversible in early-stage HL after treatment, whereas patients who develop VBDS commonly die from their disease.
  • We postulate that single-modality radiation therapy alone should be considered a valid treatment alternative in early-stage HL with idiopathic cholestasis.
  • [MeSH-major] Cholestasis / diagnosis. Cholestasis / etiology. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adult. Bile Ducts / pathology. Biopsy. Humans. Jaundice. Liver / pathology. Male. Paraneoplastic Syndromes / metabolism. Positron-Emission Tomography. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Cholestasis.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879775.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Guven S, Ozcebe OI, Tuncer ZS: Non-Hodgkin's lymphoma complicating pregnancy: a case report. Eur J Gynaecol Oncol; 2005;26(4):457-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma complicating pregnancy: a case report.
  • Histologic examination of the excised lymph node revealed non-Hodgkin's lymphoma (Histiocyte and T cell predominant B cell lymphoma).
  • The patient was evaluated to have Stage II B disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cesarean Section. Female. Humans. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122204.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


62. Birgegård G, Gascón P, Ludwig H: Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol; 2006 Nov;77(5):378-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY.
  • OBJECTIVES: Until recently, no prospective epidemiologic survey of lymphoma and multiple myeloma (L/MM) in European cancer patients had been conducted; furthermore, data on prevalence, incidence, and treatment patterns of L/MM were limited or unavailable.
  • METHODS: Data for a subgroup of 2360 L/MM patients in the European Cancer Anaemia Survey (ECAS) were analyzed; variables included age, gender, tumor type/stage, cancer and anemia treatment, WHO performance status, and hemoglobin (Hb) levels.
  • Anemia prevalence during ECAS was 72.9% (MM, 85.3%; non-Hodgkin's lymphoma, 77.9%; Hodgkin's disease, 57.4%); incidence in chemotherapy patients was 55.4%.
  • Factors found to significantly (P < 0.03) increase anemia risk were low initial Hb, female gender, persistent/resistant disease, and platinum chemotherapy.
  • [MeSH-major] Anemia / epidemiology. Lymphoma / epidemiology. Multiple Myeloma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Europe. Evaluation Studies as Topic. Female. Hemoglobins. Humans. Incidence. Male. Middle Aged. Neoplasm Staging / methods. Prevalence. Quality of Life. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1998 Aug;12(8):1281-7 [9697885.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1047-56 [9719114.001]
  • [Cites] Med Oncol. 1998 Aug;15 Suppl 1:S29-34 [9785334.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1500-7 [10735898.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):172-9 [11328297.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2865-74 [11387359.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2875-82 [11387360.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 8):7-14 [11395846.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2214-21 [11413508.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1617-23 [11527686.001]
  • [Cites] Hematol J. 2002;3(3):121-30 [12111647.001]
  • [Cites] Wien Med Wochenschr. 2002;152(13-14):334-42 [12168517.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1109-15 [9834824.001]
  • [Cites] Haematologica. 1998 Nov;83(11):993-7 [9864919.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 6;91(19):1616-34 [10511589.001]
  • [Cites] Oncologist. 2004;9 Suppl 5:55-69 [15591423.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1797-802 [15479721.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2597-605 [15452188.001]
  • [Cites] Oncology. 2006;70(1):34-48 [16493206.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2303-20 [12239138.001]
  • [Cites] Mayo Clin Proc. 2003 Jan;78(1):21-33 [12528874.001]
  • [Cites] Oncologist. 2003;8 Suppl 1:27-30 [12626786.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):386-93 [12877665.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):394-403 [12877666.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1072-9 [12942577.001]
  • [Cites] Hematol Oncol. 2003 Dec;21(4):169-80 [14735555.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1301-7 [15051778.001]
  • [Cites] Eur J Cancer. 2004 Oct;40(15):2201-16 [15454245.001]
  • [Cites] Eur J Cancer. 2004 Oct;40(15):2293-306 [15454256.001]
  • [Cites] Mayo Clin Proc. 1975 Jan;50(1):29-40 [1110582.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1618-26 [1651993.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):88-91 [8538748.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):43-6 [9671330.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):54-7 [9671332.001]
  • (PMID = 17044835.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Hemoglobins
  • [Other-IDs] NLM/ PMC1618958
  •  go-up   go-down


63. Bonnet C, Beguin Y, Fassotte MF, Seidel L, Luyckx F, Fillet G: Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma. Eur J Haematol; 2007 May;78(5):399-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
  • BACKGROUND: Several papers have reported an association of high CA125 serum levels with advanced non-Hodgkin's lymphoma (NHL) as well as a relationship between high CA125 values and poor outcome.
  • PATIENTS AND METHODS: Ninety-nine patients with NHL or Hodgkin's disease (HD) underwent serum CA125 assessment at diagnosis.
  • Gender, age, presence of B symptoms, performance status (PS), histology, sites of tumor involvement, presence of effusion, clinical stage, age-adjusted International Prognostic Index, C-reactive protein (CRP), Hb, lactate deshydrogenase (LDH) and beta2-microglobulin were evaluated for their association with serum CA125 levels.
  • RESULTS: CA125 serum levels were elevated in 34% of the patients, including 19% of patients with aggressive NHL, 45% of patients with indolent NHL, and 29% of patients with HD.
  • Univariate analyses showed that CA125 levels correlated with poor PS, the presence of B symptoms, advanced clinical stage, abdominal, bone marrow or mediastinal involvement, presence of effusions, high aaIPI, low Hb levels and high CRP, LDH or beta2-microglobulin levels.
  • In univariate analyses, OS and PFS were affected by age (PFS only), poor PS, B symptoms, advanced clinical stage, bone marrow or abdominal involvement (PFS only), high aaIPI, low Hb, high CRP or beta2-microglobulin levels.
  • CONCLUSION: While CA125 serum level correlates significantly with a number of features associated with more aggressive disease, it does not enhance the performance of standard prognostic markers in the management of patients with NHL or HD.
  • [MeSH-major] CA-125 Antigen / blood. Hodgkin Disease / blood. Lymphoma, Non-Hodgkin / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419741.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


64. Baijal G, Vadiraja BM, Fernandes DJ, Vidyasagar MS: Diffuse large B-cell lymphoma of the uterine cervix: a rare case managed novelly. J Cancer Res Ther; 2009 Apr-Jun;5(2):140-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma of the uterine cervix: a rare case managed novelly.
  • Non-Hodgkin's lymphoma (NHL) of the uterine cervix is exceedingly rare.
  • The management of the disease is not standardized.
  • She was diagnosed as stage IE after staging work-up, and managed with three courses of rituximab, cyclophosphamide, vincristine, adriamycin, and prednisolone followed by external beam radiotherapy (46 Gy in 23 fractions) by 3D conformal technique.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542675.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


65. Benjamin JE, Chen GL, Cao TM, Cao PD, Wong RM, Sheehan K, Shizuru JA, Johnston LJ, Negrin RS, Lowsky R, Laport GG: Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. Bone Marrow Transplant; 2010 Feb;45(2):303-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure.
  • Patients with diffuse large B-cell lymphoma (DLBCL) who do not achieve a complete response to front-line combination chemotherapy are often offered high-dose therapy and autologous hematopoietic cell transplantation (AHCT).
  • By univariate analyses, the following characteristics did not significantly impact OS: disease stage at diagnosis, age-adjusted IPI (International Prognostic Index) score, age > or =40 years, earlier radiotherapy and the use of FTBI in the conditioning regimen.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Aug 1;96(3):864-9 [10910898.001]
  • [Cites] Br J Haematol. 2008 Sep;142(5):786-92 [18564354.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2399-404 [11001890.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(5A):555-62 [11071261.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):406-13 [11208832.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Br J Haematol. 2002 Jan;116(1):229-35 [11841421.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2344-52 [11981006.001]
  • [Cites] Blood. 2003 Jul 15;102(2):749-55 [12663455.001]
  • [Cites] Blood. 2004 Feb 1;103(3):777-83 [12907446.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1504-9 [15367411.001]
  • [Cites] J Clin Oncol. 1988 Jul;6(7):1118-24 [3292712.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):423-31 [1999711.001]
  • [Cites] J Clin Oncol. 1992 Dec;10(12):1949-54 [1453209.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1169-76 [8201379.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3334-41 [7538824.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):214-9 [8558200.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):534-42 [8636768.001]
  • [Cites] Ann Oncol. 1996 Dec;7(10):1043-9 [9037363.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):711-7 [15581541.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4652-61 [15837965.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Br J Haematol. 2000 Sep;110(3):631-7 [10997975.001]
  • (PMID = 19597427.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA049605-18; United States / NCI NIH HHS / CA / P01 CA049605; United States / NCI NIH HHS / CA / P01 CA049605-18; United States / NCI NIH HHS / CA / P01-CA 49605
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ NIHMS205199; NLM/ PMC2886804
  •  go-up   go-down


66. Ennibi K, Mikdame M, Rabhi M, Jroundi I, Benkirane A, Chaari J, Toloune F: [Primary gastric lymphoma: a retrospective series of 35 cases]. Tunis Med; 2008 May;86(5):457-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastric lymphoma: a retrospective series of 35 cases].
  • BACKGROUND: Primary gastric non Hodgkin's lymphoma (PGNHL) is the most common site of extranodal malignant lymphoma.
  • 20 (57.1%) were in stage IE/IIE1.
  • 15 patients (42.8%) were in stage IIE2,IIIE,IVE.
  • These patients were treated with primary surgery with or without chemotherapy (11; 31.4%); primary chemotherapy (CT) alone with surgery in one patient (21; 60%) and three patients with gastric MALT lymphoma were treated by Helicobacter pylori eradication.
  • There was no significant difference in the 5 year survival rate between the patients with low grade lymphoma and the patients with large grade lymphoma (75% versus 60%, P = 0.467).
  • The 5-year survival rates for stage I/IIE1 and IIE2/III/IV patients were 80%, 53.3% respectively (p < 0.144).
  • Of the 3 patients with low-grade mucosa-associated lymphoid tissue (MALT) lymphoma with only oral anti-Helicobacter pylori regimen remained disease-free after a median follow-up of two years.
  • CONCLUSIONS: This study suggested that primary surgical resection may be important factor predicting the long-term survival of patients with primary gastric NHL. H. pylori eradication therapy was an effective first-line treatment for patients with gastric MALT lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Female. Humans. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469300.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


67. Connors JM: State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol; 2005 Sep 10;23(26):6400-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] State-of-the-art therapeutics: Hodgkin's lymphoma.
  • Presently Hodgkin's lymphoma can be cured in at least 80% of patients.
  • The major challenge to the clinician in 2005 is how to cure the disease while inducing the least irreversible toxicity.
  • This review focuses on clinical trials and institutional experiences to identify the best choice of treatment, individualized to the stage of the lymphoma permitting minimization of late toxicity such as infertility, premature menopause, cardiac disease, and most importantly, risk of second neoplasms.
  • More than 90% of patients with limited Hodgkin's lymphoma can be cured with either short-course chemotherapy alone or even briefer chemotherapy followed by involved-field radiation.
  • Accumulating evidence suggests that chemotherapy alone is suitable for the large majority of patients with limited disease.
  • For the 80% of patients with advanced disease but without a large number of adverse prognostic factors, standard multi-agent chemotherapy with the well-established ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) provides the best balance of effectiveness and minimization of toxicity.
  • In 2005 it is insufficient to focus solely on cure of Hodgkin's lymphoma.
  • Fortunately, brief chemotherapy alone or with radiation for patients with limited disease and standard ABVD chemotherapy for patients with advanced disease offer the appropriate balance of these two requirements.
  • Patients with advanced disease plus multiple indicators of a poor prognosis and patients with disease that persists despite optimized primary treatment require specially intensified treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Severity of Illness Index. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155026.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 72
  •  go-up   go-down


68. Colović M, Matić S, Kryeziu E, Tomin D, Colović N, Atkinson HD: Outcomes of primary thyroid non-Hodgkin's lymphoma: a series of nine consecutive cases. Med Oncol; 2007;24(2):203-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of primary thyroid non-Hodgkin's lymphoma: a series of nine consecutive cases.
  • Primary non-Hodgkin's lymphoma (NHL) of the thyroid gland is a rare disease with an incidence of 0.5 per 100,000 population.
  • Five patients had disease stage IE and 4 stage IIE.
  • Pathohistology and immunohistochemistry identified two patients with mucosa-associated lymphoid tissue (MALT), three follicular center cell lymphoma (FCC), two patients large B-cell lymphoma (BLCL), one a marginal zone lymphoma (MZL), and one patient a peripheral T-cell lymphoma (PTCL).
  • The PTCL patient, a 34-yr-old man, died from disseminated disease at 13 mo despite secondary chemotherapy, and one LBCL patient with extensively invasive local disease died from stroke 17 mo after diagnosis.
  • With appropriate therapy primary thyroid NHL has a favorable course; however, prognosis depends on the histology, local spread, and the stage of the disease at presentation, as well as the patient's performance status.
  • Peripheral T-cell lymphoma carries a poor prognosis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Thyroid Neoplasms / pathology. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Thyroid Gland / pathology. Thyroid Gland / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2005 Jul;55(7):425-30 [15982218.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):929-33 [1555984.001]
  • [Cites] Acta Oncol. 1996;35(4):457-62 [8695161.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):599-604 [8226154.001]
  • [Cites] Ann Oncol. 2004 May;15(5):821-30 [15111353.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):338-41 [11352307.001]
  • [Cites] N Engl J Med. 1985 Mar 7;312(10):601-4 [3838363.001]
  • [Cites] Am Surg. 1998 Mar;64(3):234-8 [9520813.001]
  • [Cites] Am J Clin Pathol. 1999 Aug;112(2):263-70 [10439808.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Feb;11(2):365-70 [3918965.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1813-21 [3759532.001]
  • [Cites] Am J Clin Oncol. 2004 Apr;27(2):178-84 [15057158.001]
  • [Cites] Eur J Surg Oncol. 1992 Aug;18(4):313-21 [1521621.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1807-12 [2428787.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1994;6(5):300-4 [7826922.001]
  • [Cites] Cancer. 1994 Jan 1;73(1):200-6 [8275426.001]
  • [Cites] Hum Pathol. 1988 Nov;19(11):1315-26 [3141260.001]
  • [Cites] Radiology. 1969 Mar;92(4):812-6 [5767761.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):623-39 [10800981.001]
  • [Cites] JAMA. 1979 Oct 19;242(16):1743-6 [480599.001]
  • [Cites] Cancer. 1980 Dec 1;46(11):2356-9 [7002279.001]
  • [Cites] Cancer. 1977 Apr;39(4):1587-602 [322838.001]
  • (PMID = 17848745.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Corazzelli G, Russo F, Capobianco G, Marcacci G, Della Cioppa P, Pinto A: Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol; 2006 May;17 Suppl 4:iv18-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
  • BACKGROUND: The prognosis of patients with aggressive non-Hodgkin's lymphoma (NHL) relapsing or progressing after front-line therapy remains poor.
  • RESULTS: Fourteen patients (median age 63 years, range 37-78 years) with relapsed (n = 9) or primary progressive (n = 5) aggressive (diffuse large cell, mantle cell, follicular G3), advanced (stage IV 71%), poor risk (IPI 3-5 50%) NHL were accrued in this pilot study.

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702180.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 4F4X42SYQ6 / Rituximab; B76N6SBZ8R / gemcitabine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


70. Glotzbecker MP, Kersun LS, Choi JK, Wills BP, Schaffer AA, Dormans JP: Primary non-Hodgkin's lymphoma of bone in children. J Bone Joint Surg Am; 2006 Mar;88(3):583-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of bone in children.
  • BACKGROUND: Primary non-Hodgkin's lymphoma of bone, often more simply referred to as primary lymphoma of bone, is a rare subset of non-Hodgkin's lymphoma in children.
  • There are only a few small series of primary lymphoma of bone in children with long-term follow-up, and none have appeared in the orthopaedic literature.
  • METHODS: A review of our institution's Pediatric Tumor Registry identified fifteen cases of primary lymphoma of bone among 306 cases of diagnosed non-Hodgkin's lymphoma between 1970 and 2003.
  • Five patients died: three of disease progression, one of treatment-related complications, and one of an unrelated cause.
  • In the summary analysis of cases collected from the literature, advanced stage, young age, non-large-cell histology, and multiple-bone involvement were predictive of poor survival (p < 0.05).
  • CONCLUSIONS: On the basis of the present series and a comprehensive review of similar series in the literature involving patients with primary lymphoma of bone, it appears that younger age, advanced-stage disease, multiple-bone involvement, and non-large-cell histology are associated with decreased survival as compared with older age, localized disease, single-bone involvement, and large-cell histology, respectively.
  • [MeSH-major] Bone Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16510826.001).
  • [ISSN] 0021-9355
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Brianzoni E, Rossi G, Ancidei S, Berbellini A, Capoccetti F, Cidda C, D'Avenia P, Fattori S, Montini GC, Valentini G, Proietti A, Algranati C: Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume. Eur J Nucl Med Mol Imaging; 2005 Dec;32(12):1392-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty-eight patients were examined, 24 with lung cancer (17 non-small cell and seven small cell) and four with non-Hodgkin's lymphoma in the head and neck region.
  • RESULTS: Three patient were excluded from the study owing to change in the disease stage subsequent to the PET/CT study.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Computer-Assisted / methods. Reproducibility of Results. Sensitivity and Specificity. Subtraction Technique

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1491. Algranati, Carlo [added]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):137S-146S [12527573.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):4-5 [15093892.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2500-7 [12815135.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1249-57 [11286831.001]
  • [Cites] J Nucl Med. 2004 Apr;45(4):543-52 [15073248.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):593-7 [10348289.001]
  • [Cites] Am J Clin Oncol. 1996 Aug;19(4):416-21 [8677917.001]
  • [Cites] Lung Cancer. 1998 Mar;19(3):167-77 [9631364.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):294-301 [12527041.001]
  • [Cites] Semin Radiat Oncol. 2001 Jan;11(1):83-92 [11146045.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):5-15 [12504030.001]
  • [Cites] Br J Radiol. 1998 Jun;71(846):587-94 [9849380.001]
  • [Cites] Radiology. 1994 May;191(2):371-7 [8153308.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):339-50 [11872279.001]
  • [Cites] Radiother Oncol. 2000 Jun;55(3):317-24 [10869746.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):78-86 [15093902.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] Radiother Oncol. 2003 Dec;69(3):237-45 [14644482.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):551-60 [10837935.001]
  • [Cites] J Nucl Med. 2004 Jan;45 Suppl 1:96S-101S [14736840.001]
  • [Cites] Lung Cancer. 1999 Feb;23 (2):105-14 [10217614.001]
  • [Cites] Rays. 2002 Jul-Sep;27(3):157-73 [12696245.001]
  • [Cites] Radiother Oncol. 2002 Jan;62(1):27-36 [11830310.001]
  • [Cites] Cancer. 2001 Aug 15;92 (4):886-95 [11550162.001]
  • [Cites] Semin Nucl Med. 2004 Oct;34(4):293-9 [15493006.001]
  • [Cites] Lancet Oncol. 2001 Mar;2(3):157-64 [11902566.001]
  • [Cites] Radiother Oncol. 2002 Jan;62(1):51-60 [11830312.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):353-9 [12023139.001]
  • (PMID = 16133395.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


72. Wu H, Ma Y, Zhu Y, Shen Y, Gu C, Ye Z, Lin H: Expression of BIRC7 protein and mRNA in non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Jun;47(6):1110-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of BIRC7 protein and mRNA in non-Hodgkin's lymphoma.
  • We investigated the expression of BIRC7, survivin, Bcl-2, Bax, p53 and p170 proteins in 167 cases of non-Hodgkin's lymphoma (NHL) and 10 cases of non-specific lymphadenitis by tissue microarray-based immunohistochemistry.
  • BIRC7 expression did not correlate with clinic pathologic factors such as sex, age, stage and grade, but overexpression of BIRC7 was positively correlated with aggression of NHL cells (P < 0.05).
  • [MeSH-major] Adaptor Proteins, Signal Transducing / biosynthesis. Apoptosis. Gene Expression Regulation, Neoplastic. Inhibitor of Apoptosis Proteins / biosynthesis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / biosynthesis. RNA, Neoplasm / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Female. Humans. Jurkat Cells. K562 Cells. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840203.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BIRC7 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Neoplasm
  •  go-up   go-down


73. Sieniawski M, Franklin J, Nogova L, Glossmann JP, Schober T, Nisters-Backes H, Diehl V, Josting A: Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol; 2007 May 20;25(15):2000-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
  • PURPOSE: To evaluate treatment outcome of patients with early-stage favorable Hodgkin's lymphoma (HL) who experience disease relapse after primary treatment with two cycles of chemotherapy followed by radiotherapy (RT).
  • PATIENTS AND METHODS: Of 1,129 patients with early-stage favorable HL enrolled onto the HD7/HD10/HD13 trials of the German Hodgkin Study Group, 42 patients were identified with treatment failure, of whom eight had primary progressive disease, seven had early relapse (< or = 12 months), and 27 had late relapse (> 12 months).
  • According to the prognostic score for relapsed HL (duration of first remission, clinical stage, and anemia at relapse), patients with two or three poor prognostic features had a significantly worse outcome compared with patients with none or one of these factors (P < .05 for FF2F and OS).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease Progression. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Risk Factors. Salvage Therapy. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17420510.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Josting A, Nogová L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Müller RP, Diehl V, Engert A: Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol; 2005 Mar 1;23(7):1522-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
  • PURPOSE: To evaluate treatment outcome and prognostic factors in patients with refractory or first relapsed Hodgkin's disease (HD) treated with salvage radiotherapy (SRT) alone.
  • PATIENTS AND METHODS: From 4,754 patients registered in the database of the German Hodgkin Study Group from 1988 to 1999, 624 patients were identified with progressive disease (n = 202), or with early (n = 170) or late (n = 252) relapsed HD.
  • Patient characteristics were: median age, 36 years; progressive disease, 47%; early relapse, 23%; late relapse, 30%; and "B" symptoms, 14%.
  • In multivariate analysis, significant prognostic factors for OS were B symptoms (P = .018) and stage at relapse (P = .014).
  • In patients with limited stage at progression/relapse, duration of first remission was significant (P = .04) for FF2F.
  • CONCLUSION: SRT offers an effective treatment for selected subsets of patients with relapsed or refractory HD.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Male. Middle Aged. Prednisone / therapeutic use. Procarbazine / therapeutic use. Radiotherapy / adverse effects. Retrospective Studies. Survival Rate. Treatment Failure. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15632410.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; COPP protocol
  •  go-up   go-down


75. Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D: Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol; 2006 Sep 1;24(25):4123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
  • PURPOSE: To evaluate the safety and efficacy of rituximab adjunction to the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: HIV-seropositive patients with high-grade lymphoma of B-cell origin were eligible if they had no more than one of the following characteristics: CD4 cell count less than 100/microL, prior AIDS, or performance status less than 2.
  • This multicenter phase II trial evaluated the response rate and disease-free survival after six courses of rituximab plus CHOP.
  • Characteristics of patients were median age, 41 years; median CD4 cells, 172/microL; histology, diffuse large B-cell lymphoma (n = 42), immunoblastic (n = 2), Burkitt lymphoma (n = 16), and plasmablastic (n = 1); 42 patients with stage III to IV; International Prognostic Index 0 to 1 (n=31), and 2 to 3 (n = 27).
  • Eighteen patients died: 16 as a result of lymphoma, one as a result of infection, and one as a result of encephalitis.
  • CONCLUSION: Rituximab adjunction to CHOP produced a CR rate of 77% and a 2-year survival rate of 75% in patients with AIDS-related non-Hodgkin's lymphoma, without increasing the risk of life-threatening infections.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Risk Factors. Rituximab. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Feb 20;25(6):e6 [17308260.001]
  • [CommentIn] J Clin Oncol. 2007 Feb 20;25(6):e7 [17308261.001]
  • (PMID = 16896005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


76. Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M, Intergruppo Italiano Linfomi: ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol; 2005 Dec 20;23(36):9198-207
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
  • PURPOSE: In this multicenter, prospective, randomized clinical trial on advanced Hodgkin's lymphoma (HL), the efficacy and toxicity of two chemotherapy regimens, doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone (Stanford V) and mechlorethamine, vincristine, procarbazine, prednisone, epidoxirubicin, bleomycin, vinblastine, lomustine, doxorubicin, and vindesine (MOPPEBVCAD), were compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as standard therapy to select which regimen would best support a reduced radiotherapy program, which was limited to < or = two sites of either previous bulky or partially remitting disease (a modification of the original Stanford program).
  • PATIENTS AND METHODS: Three hundred fifty-five patients with stage IIB, III, or IV HL were randomly assigned.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Lomustine / administration & dosage. Male. Mechlorethamine / administration & dosage. Melphalan / administration & dosage. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage. Vindesine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Dec 20;23(36):9058-62 [16314611.001]
  • (PMID = 16172458.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; Q41OR9510P / Melphalan; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; ABVD protocol; MOPPEBVCAD protocol; Stanford V protocol
  •  go-up   go-down


77. Moreno M, Sancho JM, Gardella S, Coll R, García O, Gallardo D, Ribera JM: [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients]. Med Clin (Barc); 2010 Jan 30;134(2):72-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
  • BACKGROUND AND OBJECTIVES: Non-pegylated liposomal doxorubicin is associated with lower cardiac toxicity than conventional doxorubicin, and for that reason it has been used in the treatment of non-Hodgkin's lymphoma (NHL) in old patients or patients with cardiac disease.
  • The most frequent histological diagnosis was diffuse large B cell lymphoma (DLBCL, 20 patients).
  • The stage disease at diagnosis was III/IV in 19 (73%) patients whereas 12 (57%) of the 21 patients with DLBCL and grade 3 follicular lymphoma had a high-risk International Prognostic Index.
  • The most frequent cardiovascular risk factor was hypertension (50% of the patients) and 6 (23%) had previous heart disease.
  • Two patients died after the first cycle of chemotherapy (one because of sudden death and the other due to disease progression).
  • The median overall survival was 50,7 months (95% confidence interval [95% CI] 8-93.3) and the median disease free survival was 18,4 months (95% CI 18.1-18.7).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Liposomes. Male. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Rituximab. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 19913261.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Liposomes; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


78. Di Lucca-Chrisment J, Maubec E, Grossin M, Marinho E, Varet B, Maillard H, Crickx B: [Long-term efficacy of autologous stem cell transplantation for stage IV mycosis fungoides]. Ann Dermatol Venereol; 2009 Nov;136(11):800-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term efficacy of autologous stem cell transplantation for stage IV mycosis fungoides].
  • BACKGROUND: Mycosis fungoides during large cell transformation to lymphoma has a poor prognosis with mean survival of 36 months.
  • CASE REPORT: A 25-year-old man presenting eczema-like patches since childhood was treated by chemotherapy for multiple lymphadenopathies considered as Hodgkin's lymphoma.
  • Non-infiltrated patches showed small T-cell lymphoma with epidermotropism.
  • Despite multiple courses of chemotherapy, the disease progressed, with neurological involvement in particular.
  • DISCUSSION: This was probably a case of juvenile mycosis fungoides diagnosed and transformed in adult age.
  • [MeSH-minor] Adolescent. Adult. Biopsy. Humans. Leg / pathology. Male. Skin / pathology. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917433.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


79. Kumar R, Sidhu H, Mistry R, Shet T: Primary pulmonary Hodgkin's lymphoma: a rare pitfall in transthoracic fine needle aspiration cytology. Diagn Cytopathol; 2008 Sep;36(9):666-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary Hodgkin's lymphoma: a rare pitfall in transthoracic fine needle aspiration cytology.
  • Primary pulmonary Hodgkin's lymphoma (PPHL) is extremely rare.
  • At an extranodal location such as the lung this lymphoma is likely to be confused with the more commonly occurring carcinomas at this site.
  • In view of the locally advanced stage, patient received a carboplatin and gemcite-based chemotherapy with complete response but postchemotherapy patient refused local surgery.
  • Two years later, the patient developed enlarged nodes which were diagnosed as Hodgkin's lymphoma, and a review of prior lung tumor confirmed the diagnosis of PPHL.
  • [MeSH-major] Diagnostic Errors. Hodgkin Disease / diagnosis. Hodgkin Disease / pathology. Lung / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Humans. Male. Radiography, Thoracic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677750.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM: Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol; 2009 Jul 10;27(20):3346-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
  • PURPOSE: This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating veltuzumab, a humanized anti-CD20 antibody with structure-function differences from chimeric rituximab.
  • PATIENTS AND METHODS: Eighty-two patients (median age, 64 years; 79% stage III/IV, one to nine prior treatments) received four once-weekly doses of 80 to 750 mg/m(2) of veltuzumab and were assessed for safety, efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity.
  • In follicular lymphoma, 24 (44%) of 55 patients had objective responses (OR), with 15 (27%) complete responses (CRs) or CRs unconfirmed (CRus) by International Working Group criteria, and with some responses occurring despite two to five prior rituximab-containing regimens, less favorable prognosis (elevated lactate dehydrogenase, tumors > 5 cm, and Follicular Lymphoma International Prognostic Index > or = 2), and at all dose levels.
  • In marginal zone lymphoma, five (83%) of six patients had ORs, with two CRs/CRus (33%), and in diffuse large B-cell lymphoma, three (43%) of seven patients achieved partial responses.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Fever / chemically induced. Headache / chemically induced. Humans. Kaplan-Meier Estimate. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Male. Middle Aged. Pruritus / chemically induced. Recurrence. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00285428/ NCT00596804
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / veltuzumab
  •  go-up   go-down


81. Chen CQ, Yin L, Peng CH, Zhao R, Chen GM, Zhou HJ, Li HW: [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May;10(3):249-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases].
  • OBJECTIVE: To study the clinical characteristics,treatment and prognosis of primary non-Hodgkin's lymphoma of small bowel.
  • METHODS: The records of 34 patients with a confirmed diagnosis of primary non-Hodgkin's lymphoma of small bowel, registered between Jan.
  • RESULTS: Twenty-seven patients had B-cell lymphoma and 7 had T-cell lymphoma of the small bowel.
  • According to Ann Arbor staging classification, 22 patients belonged to stage I~II, including 20 cases of B-cell lymphoma and 2 cases of T-cell lymphoma, and 12 patients belonged to stage III~IV, including 7 cases of B-cell lymphoma and 5 cases of T-cell lymphoma.
  • Compared with T-cell lymphoma patients, B-cell lymphoma patients had lower lymphoma stages (P<0.05).
  • T-cell lymphoma patients were more often treated with emergent operation than B-cell lymphoma patients would (P<0.05).
  • It happened more frequently that B-cell lymphoma patients reached complete remission and their accumulative survival rate was longer than T-cell lymphoma patients did (P<0.05).
  • CONCLUSION: Patients with stages I and II B-cell lymphoma of small bowel respond well to surgery and chemotherapy, and the treatment and prognosis of patients with T-cell lymphoma of small bowel are unsatisfactory.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies


82. Hohaus S, Giachelia M, Di Febo A, Martini M, Massini G, Vannata B, D'Alo' F, Guidi F, Greco M, Pierconti F, Larocca LM, Voso MT, Leone G: Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol; 2007 Aug;18(8):1376-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma.
  • BACKGROUND: In Hodgkin's lymphoma (HL), the production of cytokines by Reed-Sternberg cells and the surrounding tissue is thought to contribute to the biology of the disease.
  • In the Cox multivariate analysis, the IL-10-592AA, the IL-6-174GG genotypes and stage were independent prognostic factors.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496310.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10
  •  go-up   go-down


83. Schumacher YO, Muser K, Hirschberger B, Roecker K, Dickhuth HH, Pottgiesser T: Hodgkin's Lymphoma in an elite endurance athlete. Med Sci Sports Exerc; 2008 Mar;40(3):401-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's Lymphoma in an elite endurance athlete.
  • He was subsequently diagnosed with stage III A (S) Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / diagnosis. Sports
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Germany. Hemoglobins / analysis. Humans. Male. Physical Endurance. Prednisone / administration & dosage. Procarbazine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379199.001).
  • [ISSN] 0195-9131
  • [Journal-full-title] Medicine and science in sports and exercise
  • [ISO-abbreviation] Med Sci Sports Exerc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; BEACOPP protocol
  •  go-up   go-down


84. Wang W, Gao L, Wang LL, Li MY, Li YY, Zhao W, Xu YY, Ding Y, Yu L: [Detection of bone marrow involvement by lymphoma cells in patients with B-NHL by using flow cytometry analysis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1204-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of bone marrow involvement by lymphoma cells in patients with B-NHL by using flow cytometry analysis].
  • This study was purposed to investigate the significance of using (FCM) flow cytometry for detection bone marrow involvement by lymphoma cells in untreated patients with B cell non-Hodgkin's lymphoma (B-NHL).
  • Even in patients with early stage, lymphoma cells still could be detected by FCM in involved bone marrow.
  • Evaluation whether the bone marrow has been involved by lymphoma cells should be recommend to every patient with B-NHL before chemotherapy and every disease stages.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129261.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


85. Liu HW, Seftel MD, Rubinger M, Szwajcer D, Demers A, Nugent Z, Schroeder G, Butler JB, Cooke A: Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2010 Oct 1;78(2):513-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
  • PURPOSE: The optimal preparative regimen for non-Hodgkin's lymphoma patients undergoing autologous peripheral blood stem cell transplantation (PBSCT) is unknown.
  • We compared the acute and long-term toxicities, disease relapse-free survival, and overall survival (OS).
  • The 5-year disease relapse-free survival rate was 50.0% and 50.7% in the CY/E/TBI and BEAM groups, respectively (p = .808).
  • The univariate analysis results indicated that patients with Stage IV, with chemotherapy-resistant disease, and who had received PBSCT before 2000 had inferior OS.
  • CONCLUSION: A 12-Gy TBI-based conditioning regimen for PBSCT for non-Hodgkin's lymphoma resulted in disease relapse-free survival and OS similar to that after BEAM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunosuppressive Agents / therapeutic use. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation / methods. Transplantation Conditioning / methods. Whole-Body Irradiation / methods
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Carmustine / administration & dosage. Cyclophosphamide / therapeutic use. Cytarabine / administration & dosage. Disease-Free Survival. Dose Fractionation. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Male. Manitoba. Melphalan / administration & dosage. Middle Aged. Radiation Pneumonitis / etiology. Retrospective Studies. Survival Rate. Time Factors. Transplantation, Autologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20137862.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen
  •  go-up   go-down


86. Ozer N, Deveci OS, Kaya EB, Demircin M: Mediastinal lymphoma causing extrinsic pulmonary stenosis. Turk Kardiyol Dern Ars; 2009 Sep;37(6):421-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal lymphoma causing extrinsic pulmonary stenosis.
  • The pathological diagnosis of the mass was stage IIa nodular sclerosing Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma / complications. Mediastinal Neoplasms / complications. Pulmonary Valve Stenosis / etiology
  • [MeSH-minor] Echocardiography, Transesophageal. Female. Humans. Pulmonary Artery / surgery. Pulmonary Artery / ultrasonography. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20019459.001).
  • [ISSN] 1016-5169
  • [Journal-full-title] Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
  • [ISO-abbreviation] Turk Kardiyol Dern Ars
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


87. Hwang YC, Kim TY, Kim WB, Shong YK, Yi KH, Shong M, Jo YS, Kim WS, Chung JH: Clinical characteristics of primary thyroid lymphoma in Koreans. Endocr J; 2009;56(3):399-405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of primary thyroid lymphoma in Koreans.
  • Primary thyroid lymphoma is a very rare tumor and its prevalence is approximately 0.1% of all thyroid cancers in Korea.
  • Therefore, we performed this study to investigate the clinical characteristics of primary thyroid lymphoma in Koreans.
  • We retrospectively analyzed the medical records of the 44 patients with primary thyroid lymphoma from 1991 to 2006 at four major referral hospitals in Korea.
  • All but two patients had non-Hodgkin's lymphoma with B cell origin, and eighty percent of patients presented with stage IE or IIE.
  • Twenty-one of 44 patients (48%) had diffuse large B cell lymphoma (DLBCL) and 17 (39%) had MALT lymphoma.
  • Malignancies originating from lymphoid cells were suspected in 10 of eighteen patients with DLBCL (56%) by using fine-needle aspiration cytology (FNAC), and no difference was noted compared with MALT lymphoma (64%).
  • Compared with DLBCL, the patients with MALT lymphoma were more frequently presented with stage I disease (DLBCL vs. MALT lymphoma: 32% vs. 65%, P=0.04).
  • Moreover, in contrast to DLBCL, most of the patients with MALT lymphoma achieved complete response with treatments (DLBCL vs. MALT lymphoma: 53% vs. 94%, P<0.01).
  • The patients with MALT lymphoma were more frequently presented with early stage diseases and this might lead to the favorable outcome to treatments than those with DLBCL.
  • [MeSH-major] Lymphoma / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Asian Continental Ancestry Group. Biopsy, Fine-Needle. Child. Female. Hashimoto Disease / complications. Humans. Korea. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19225216.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


88. Sagan D, Semczuk A, Lampka E: Combination chemotherapy for Hodgkin's lymphoma during pregnancy: favorable outcome for mother and child. J Obstet Gynaecol Res; 2010 Aug;36(4):882-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy for Hodgkin's lymphoma during pregnancy: favorable outcome for mother and child.
  • We report a case of stage IIA nodular sclerosis Hodgkin's lymphoma (HL), diagnosed in a 24-year-old woman at 18 weeks of gestation.
  • Individualized combination chemotherapy according to etoposide-vinblastine-doxorubicin (EVA) regimen was administered, resulting in effective local control of the disease and improvement in the patient's general condition.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Hodgkin Disease / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Bleomycin. Dacarbazine. Disease-Free Survival. Doxorubicin. Etoposide. Female. Humans. Pregnancy. Treatment Outcome. Vinblastine

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666963.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol; EVA regimen
  •  go-up   go-down


89. Re A, Ferrari S, Frata P, Pizzocaro C, Crippa C, Tucci A, Facchetti F, Grazioli L, Magrini SM, Rossi G: Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study. Ann Oncol; 2008 May;19(5):951-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study.
  • BACKGROUND: Tailoring treatment intensity is critical in Hodgkin's lymphoma (HL).
  • MATERIALS AND METHODS: Patients received 4-8 adriamycin, bleomycin, vinblastine and dacarbazine courses according to stage.
  • Disease was reassessed evaluating late computed tomography scan response improvement (CTRI) and Ga-67 uptake.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. GALLIUM .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209012.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Citrates; 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 11056-06-7 / Bleomycin; 27905-02-8 / gallium citrate; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; CH46OC8YV4 / Gallium
  •  go-up   go-down


90. Zell JA, Yoon EJ, Ignatius Ou SH, Hoefs JC, Chang JC: Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab. Anticancer Drugs; 2005 Jan;16(1):83-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with stage IV non-Hodgkin's lymphoma and chronic hepatitis who was treated with chemotherapy and rituximab developed fatal reactivation of hepatitis B.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hepatitis B / chemically induced. Lymphoma, Non-Hodgkin / drug therapy. Virus Activation / drug effects
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Fatal Outcome. Hepatitis B virus / drug effects. Hepatitis B virus / physiology. Humans. Male. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Recurrence. Rituximab. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613909.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


91. Eich HT, Gossmann A, Engert A, Kriz J, Bredenfeld H, Hansemann K, Skripnitchenko R, Brillant C, Pfistner B, Staar S, Diehl V, Müller RP, German Hodgkin Study Group: A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys; 2007 Nov 15;69(4):1187-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG).
  • PURPOSE: The role of radiotherapy (RT) after intensive chemotherapy in patients with advanced stage Hodgkin's lymphoma (HL) is still unclear.
  • The German Hodgkin Study Group (GHSG) randomized HD12 trial was designed to test whether consolidative RT in the region of initial bulky disease and of residual disease is necessary after effective chemotherapy.
  • METHODS AND MATERIALS: A total of 1661 patients aged 16 to 65 years with HL in Stage IIB (large mediastinal mass and/or E-lesions) or Stage III to IV were randomized from January 1999 to January 2003 according to a factorial design between: 8 esc.BEACOPP + RT (arm A), 8 esc.BEACOPP non-RT (arm B), 4+4BEACOPP + RT (arm C), 4+4BEACOPP non-RT (arm D).
  • The panel defined initial bulky disease in 800 patients and residual disease in 600 patients.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Combined Modality Therapy / methods. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Middle Aged. Neoplasm, Residual. Prednisone / administration & dosage. Procarbazine / administration & dosage. Quality Assurance, Health Care. Radiotherapy / standards. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17703895.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; BEACOPP protocol
  •  go-up   go-down


92. Makinson A, Martelli N, Peyrière H, Turriere C, Le Moing V, Reynes J: Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease. Eur J Haematol; 2007 Apr;78(4):358-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease.
  • A HIV infected patient was treated for stage IVB Hodgkin's lymphoma by ABVD (doxorubicine, bleomycine, vinblastine, dacarbazine) chemotherapy and lopinavir-ritonavir based antiretroviral therapy inducing profound life-threatening neutropenia.
  • [MeSH-major] Anti-HIV Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Neutropenia / chemically induced. Vinblastine / adverse effects
  • [MeSH-minor] Adult. Humans. Male. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378895.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


93. Tanaka PY, Pracchia LF, Calore EE: Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: the experience of a single center in Brazil. Int J Hematol; 2006 Nov;84(4):337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: the experience of a single center in Brazil.
  • The relative risk of non-Hodgkin's lymphoma (NHL) among patients infected with human immunodeficiency virus (HIV) is elevated compared with the general population.
  • A univariate analysis showed a significant CR rate in patients with respect to the following factors: no acquired immunodeficiency syndrome (AIDS) diagnosis prior to the lymphoma, disease stage of I to II, and an International Prognostic Index (IPI) of low or low-intermediate risk.
  • A median disease-free survival (DFS) time for the patients who achieved a CR was not reached, with a mean survival time of 73 months and a 3-year DFS rate of 77.5%.
  • Our results provide additional information regarding HIV-related lymphoma in Brazil.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Brazil. Cyclophosphamide. Disease-Free Survival. Doxorubicin. Female. Humans. Male. Middle Aged. Prednisolone. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1165-73 [8118021.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Blood. 2006 Apr 1;107(7):3014-5 [16554492.001]
  • [Cites] Blood. 1992 Jul 1;80(1):8-20 [1319239.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):79-87 [10561022.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1521-9 [12824790.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Lancet. 2000 Jul 22;356(9226):291-6 [11071184.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):442-53 [10950371.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Ann Intern Med. 1985 Sep;103(3):402-3 [2992336.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Oncology (Williston Park). 2001 Apr;15(4):439-48; discussion 448-9 [11346932.001]
  • (PMID = 17118760.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


94. He YF, Zhang YJ, Li YH, Lin TY, Xia YF, Lu TX, Huang HQ, Jiang WQ, Xian CG, He YJ, Guan ZZ: [Primary non-Hodgkin's lymphoma of the nasal cavity at early stage: long-term treatment outcomes and prognostic analyses of 108 cases]. Ai Zheng; 2006 Dec;25(12):1538-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphoma of the nasal cavity at early stage: long-term treatment outcomes and prognostic analyses of 108 cases].
  • BACKGROUND & OBJECTIVE: Primary non-Hodgkin's lymphoma (NHL) of the nasal cavity has unique clinicopathologic features, and optimal treatment regimen remains unclear.
  • This study was to summarize the clinical features, treatment outcomes, and prognostic factors of primary NHL of the nasal cavity at early stage.
  • Pre-treatment history of disease, extent of primary lesion involvement, and response to the primary treatment may be independent prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin. Nasal Cavity. Nose Neoplasms. Radiotherapy, High-Energy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Proportional Hazards Models. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17166382.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; EPOCH protocol
  •  go-up   go-down


95. Sotnikov VM, Pan'shin GA, Datsenko PV, Ivashin AV, Smol'tsova NN: [The role of adjuvant radiotherapy in the complex treatment of stage III-IV aggressive non-Hodgkin's lymphoma]. Vopr Onkol; 2009;55(4):443-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of adjuvant radiotherapy in the complex treatment of stage III-IV aggressive non-Hodgkin's lymphoma].
  • Immediate and end results of chemoradiotherapy of 225 patients (average age--43 years) with primary aggressive non-Hodgkin's lymphomas stage III-IV were evaluated.
  • Stage 1 of treatment included 4-8 cycles of chemotherapy (ACOP and other standard protocols); stage 2--irradiation of residual foci with 20-50 Gy, or 20-36 Gy for originally extensive and extralymphatic foci when in full remission.
  • The disease is specific, so relapse-free survival in cases of generalized primary aggressive lymphoma in full remission remained unchanged too whatever the stage at which full remission emerged.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19947367.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


96. Suzuki T, Takeuchi M, Saeki H, Yamazaki S, Koga H, Abe D, Nishimura M, Nakaseko C, Nakasa H, Nakamura H, Ariyoshi N, Kitada M: Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy. Clin Ther; 2010 Mar;32(3):527-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy.
  • CASE SUMMARY: A 36-year-old Japanese man (height, 182 cm; weight, 83 kg; body surface area, 2.04 m(2)) was admitted to the hospital for the treatment of malignant lymphoma (clinical stage IVB Hodgkin's lymphoma).
  • [MeSH-minor] Acute Disease. Adult. Bleomycin / administration & dosage. Bleomycin / adverse effects. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Fever / chemically induced. Hodgkin Disease / drug therapy. Humans. Male. Seizures, Febrile / chemically induced. Unconsciousness / chemically induced. Vinblastine / administration & dosage. Vinblastine / adverse effects

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Excerpta Medica Inc. All rights reserved.
  • (PMID = 20399989.001).
  • [ISSN] 1879-114X
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


97. Shimabukuro-Vornhagen A, Haverkamp H, Engert A, Balleisen L, Majunke P, Heil G, Eich HT, Stein H, Diehl V, Josting A: Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. J Clin Oncol; 2005 Aug 20;23(24):5739-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
  • PURPOSE: To investigate the clinical characteristics and treatment outcome of patients with lymphocyte-rich classical Hodgkin's lymphoma (LRCHL) compared with other histologic subtypes of Hodgkin's lymphoma (HL).
  • PATIENTS AND METHODS: From a total of 2,715 patients with biopsy-proven HL treated within the trials HD7 to HD12 of the German Hodgkin's Study Group, 100 patients (4%) with LRCHL, 145 patients (5%) with lymphocyte-predominant HL (LPHL), 1,688 patients (62%) with nodular sclerosis, 731 patients (27%) with mixed cellularity, and 23 patients (1%) with lymphocyte depletion were identified.
  • RESULTS: Compared with other histologic subtypes, patients with LRCHL are, on average, older and usually present with early stages of disease (stage I, 34%; stage II, 46%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Disease Progression. Female. Germany. Humans. Lymphocytes. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 May 10;24(14):2220
  • (PMID = 16009944.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


98. Hollender A, Bjøro T, Otto Karlsen K, Kvaloy SO, Nome O, Holte H: Vitamin D deficiency in patients operated on for gastric lymphoma. Scand J Gastroenterol; 2006 Jun;41(6):673-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D deficiency in patients operated on for gastric lymphoma.
  • OBJECTIVE: To determine the nutritional status in patients treated for gastric non-Hodgkin's lymphoma (NHL).
  • Those with aggressive lymphomas in stage IE-IIE underwent gastric surgery followed by CHOP-like chemotherapy.
  • Patients with indolent lymphomas and localized disease did not receive any further treatment if the operation was considered radical; otherwise, they received local radiotherapy after surgery.
  • Patients with advanced disease underwent gastric surgery only if there was a considerable risk of bleeding or perforation.
  • [MeSH-major] Gastrectomy. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Vitamin D Deficiency / blood
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Nutritional Status. Prospective Studies. Retrospective Studies


99. Nogovà L, Diehl V, Engert A, German Hodgkin Study Group: Nodular lymphocyte-predominant Hodgkin's lymphoma. Curr Hematol Malig Rep; 2006 Mar;1(1):60-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte-predominant Hodgkin's lymphoma.
  • Lymphocyte-predominant Hodgkin's lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin's lymphoma (cHL).
  • Treatment of LPHL patients using standard Hodgkin's lymphoma protocols leads to complete remission in more than 95% of patients.
  • Survival and freedom from treatment failure are substantially worse in advanced-stage patients than for early-stage patients.
  • In contrast, patients with early-stage LPHL without risk factors might be sufficiently treated with reduced-intensity programs having less severe adverse effects.
  • IF-RT seems to be emerging as a treatment of choice for patients with stage IA LPHL; most larger study groups, such as the German Hodgkin Study Group and the European Organisation for Research and Treatment of Cancer, have adopted IF-RT as the treatment of choice for these patients.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Histiocytes / pathology. Humans. Lymphocytes / pathology. Neoplasm Staging. Patient Selection. Prognosis. Radiotherapy Dosage. Remission Induction. Rituximab. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1731-8 [11920535.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1221-9 [16094666.001]
  • [Cites] Histopathology. 1990 Feb;16(2):157-65 [2323737.001]
  • [Cites] Blood. 2004 Jan 1;103(1):188-93 [12881301.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:77-82 [2049323.001]
  • [Cites] Ann Oncol. 1995 Jul;6(6):559-65 [8573534.001]
  • [Cites] Cancer. 1987 Jan 1;59(1):99-106 [3791150.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9337-42 [9256483.001]
  • [Cites] Cancer J. 2002 Sep-Oct;8(5):377-83 [12416895.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):684-7 [12972802.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1683-7 [16093276.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5739-45 [16009944.001]
  • [Cites] Eur J Cancer. 2002 Mar;38 Suppl 4:S107-13 [11858975.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2675-81 [15231567.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1903-10 [14738141.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Feb;17(1):47-53 [15714929.001]
  • [Cites] Blood. 2003 Jan 15;101(2):420-4 [12509381.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2948-52 [12885814.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1889-99 [10961891.001]
  • (PMID = 20425333.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 25
  •  go-up   go-down


100. Russo F, Lastoria S, Svanera G, Capobianco G, de Chiara A, Francia Rd, Squame E, de Martinis F, Pinto A: Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma. Leuk Lymphoma; 2007 Apr;48(4):723-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma.
  • The present study has explored the possible value of sCA-125 as a prognostic factor in Hodgkin's lymphoma (HL).
  • From August 1992 to June 2005 sCA-125 was measured at presentation and at the end of the treatments in 221 newly diagnosed adult patients with HL.
  • In this study 90/221 (41%) patients showed a value greater than the standard upper limit of 35 U/ml, and 79/90 (88%) with an abnormal sCA-125 were at an advanced stage of the disease.
  • In addition, soluble CA-125 was not detected in supernatants coming from four different Hodgkin-derived cell lines.
  • Extranodal disease, severe lymphocytopenia and age proved to be the only standard factors that could represent a poor chance to survive.
  • [MeSH-major] CA-125 Antigen / biosynthesis. Hodgkin Disease / blood. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Remission Induction. Time Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454630.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down






Advertisement